


8514437



# THE UNITED STATES OF AMERICA

**TO ALL TO WHOM THESE PRESENTS SHALL COME:**

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*August 08, 2024*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.**

**APPLICATION NUMBER: 63/308,727**  
**FILING DATE: *February 10, 2022***

**THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS US63/308,727**



Certified by

*Katherine Kelly Vidal*

Performing the Functions and Duties of the  
Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET – Page 1 of 2**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Priority Mail Express® Label No. \_\_\_\_\_

| <b>INVENTOR(S)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                        |                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|---------------------------------------------------------|
| Given Name (first and middle [if any])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Family Name or Surname | Residence<br>(City and either State or Foreign Country) |
| PRASHANT KASHINATH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | BHAVAR                 | HYDERABAD, INDIA                                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                        |                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                        |                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                        |                                                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                        |                                                         |
| Additional inventors are being named on the _____ separately numbered sheets attached hereto.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |                                                         |
| <b>TITLE OF THE INVENTION (500 characters max):</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                        |                                                         |
| NOVEL ANTICANCER THERAPEUTICS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |                                                         |
| <div style="display: flex; justify-content: space-between;"> <span>Direct all correspondence to:</span> <span><b>CORRESPONDENCE ADDRESS</b></span> </div> <div style="display: flex; align-items: center; margin-top: 5px;"> <input checked="" type="checkbox"/> The address corresponding to Customer Number: <div style="border: 1px solid black; padding: 5px; margin-left: 10px; flex-grow: 1;">159570</div> </div> <div style="margin-top: 5px;"> <b>OR</b><br/> <input type="checkbox"/> Firm or Individual Name </div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |                                                         |
| Address                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                        |                                                         |
| City                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | State                  | Zip                                                     |
| Country                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Telephone              | Email                                                   |
| <b>ENCLOSED APPLICATION PARTS (check all that apply)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                        |                                                         |
| <div style="display: flex; justify-content: space-between;"> <div> <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76.<br/> <input type="checkbox"/> Drawing(s) Number of Sheets _____<br/> <input checked="" type="checkbox"/> Specification (e.g., description of the invention) Number of Pages <u>91</u> </div> <div> <input type="checkbox"/> CD(s), Number of CDs _____<br/> <input type="checkbox"/> Other (specify) _____ </div> </div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |                                                         |
| <b>Fees Due:</b> Filing Fee of \$300 (\$150 for small entity) (\$75 for micro entity). If the specification and drawings exceed 100 sheets of paper, an application size fee is also due, which is \$420 (\$210 for small entity) (\$105 for micro entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                        |                                                         |
| <b>METHOD OF PAYMENT OF THE FILING FEE AND APPLICATION SIZE FEE FOR THIS PROVISIONAL APPLICATION FOR PATENT</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                        |                                                         |
| <div style="display: flex; justify-content: space-between;"> <div> <input checked="" type="checkbox"/> Applicant asserts small entity status. See 37 CFR 1.27.<br/> <input type="checkbox"/> Applicant certifies micro entity status. See 37 CFR 1.29.<br/> Applicant must attach form PTO/SB/15A or Bor equivalent.<br/> <input type="checkbox"/> A check or money order made payable to the <i>Director of the United States Patent and Trademark Office</i> is enclosed to cover the filing fee and application size fee (if applicable).<br/> <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.<br/> <input checked="" type="checkbox"/> The Director is hereby authorized to charge the filing fee and application size fee (if applicable) or credit any overpayment to Deposit Account Number: <u>60-2685</u>. </div> <div style="text-align: right; width: 30%;"> <div style="border: 1px solid black; padding: 10px; display: inline-block; margin-bottom: 10px;">150.00</div> <b>TOTAL FEE AMOUNT (\$)</b> </div> </div> |                        |                                                         |

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 10 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET – Page 2 of 2**

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. (NOTE: Providing this information on a provisional coversheet, such as this Provisional Application for Patent Cover Sheet (Form PTO/SB/16), does not satisfy the requirement of 35 U.S.C. 202(c)(6), which requires that the *specification* contain a statement specifying that the invention was made with Government support and that the Government has certain rights in the invention.)



No.



Yes, the invention was made by an agency of the U.S. Government. The U.S. Government agency name is:

\_\_\_\_\_



Yes, the invention was made under a contract with an agency of the U.S. Government.

The contract number is: \_\_\_\_\_

The U.S. Government agency name is: \_\_\_\_\_

\_\_\_\_\_

In accordance with 35 U.S.C. 202(c)(6) and 37 CFR 401.14(f)(4), the specifications of any United States patent applications and any patent issuing thereon covering the invention, including the enclosed provisional application, must state the following:

“This invention was made with government support under [IDENTIFY THE CONTRACT] awarded by [IDENTIFY THE FEDERAL AGENCY]. The government has certain rights in the invention.”

**WARNING:**

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

SIGNATURE /Parithosh K Tungaturthi/ DATE 02/10/2022  
 TYPED OR PRINTED NAME Parithosh K. Tungaturthi REGISTRATION NO. 74,174  
 (if appropriate)  
 TELEPHONE 202-641-1335 DOCKET NUMBER VRT-003-USP2

## Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

## NOVEL ANTICANCER THERAPEUTICS

### FIELD OF THE INVENTION

The present invention relates to novel compounds described herein, the method of preparing the same, its pharmaceutical composition and method for use thereof. In particular the invention to compounds of formula A or their pharmaceutically acceptable salts thereof are inhibitors of KRAS protein and useful in treatment, prevention and/or amelioration of diseases or disorders associated with KRAS especially the Cancer.

### BACKGROUND OF THE INVENTION

Genes are in the DNA of each cell of human body that control how the cell functions, including: how quickly it grows, how often it divides or how long it lives. Genes control how your cells work by making proteins. The proteins have specific functions and act as messengers for the cell and each gene must have the correct instructions for making its protein. This allows the protein to perform the correct function for the cell. All cancers begin when one or more genes in a cell mutate. A mutation is a change. It creates an abnormal protein. Or it may prevent a protein's formation. An abnormal protein provides different information than a normal protein. This can cause cells to multiply uncontrollably and become cancerous.

Broadly the two basic types of genetic mutations that are referred to by researchers are (a) Acquired mutations and factors that cause these mutations include use of Tobacco, exposure to Ultraviolet (UV) radiation, Viruses or age. Cancer that occurs because of acquired mutations is called sporadic cancer. (b) Germline mutations: A germline mutations are less common and occurs in a sperm cell or egg cell. Because the mutation affects reproductive cells, it can pass from generation to generation. Cancer caused by germline mutations is called inherited cancer and accounts for about 5% to 20% of all cancers.

Many of the genes that contribute to cancer development fall into broad categories:

**DNA repair genes.** These fix mistakes made when DNA is copied. Many of them function as tumor suppressor genes. *BRCA1*, *BRCA2*, and *p53* are all DNA repair genes. If a person has an error in a DNA repair gene, mistakes remain uncorrected and the mistakes may lead to mutations. These mutations may eventually lead to cancer, particularly if the said mutations occurs in tumor suppressor genes or oncogenes.

**Tumor suppressor genes.** These are protective genes. Normally, they limit cell growth by monitoring how quickly cells divide into new cells, repairing mismatched DNA and controlling cell death. When a tumor suppressor gene mutates, cells grow uncontrollably and they may eventually form a tumor. Examples of tumor suppressor genes include *BRCA1*, *BRCA2*, and *p53* or *TP53*

**Oncogenes.** These turn a healthy cell into a cancerous cell. Mutations in these genes are not known to be inherited. The two most common oncogenes are HER2, a specialized protein that controls cancer growth and spread. It is found in some cancer cells. For example, breast and ovarian cancer cells and RAS, the gene of *RAS* family, which makes proteins involved in cell communication pathways, cell growth, and cell death.

One such mutation that has been reported, is the mutation in RAS family of genes. RAS is been known to acts as a molecular switch and is a monomeric globular proteins that is associated with the plasma membrane. RAS can either bind to guanosine 5'-diphosphate (GDP) (known as a Resting or in inactive state) or guanosine-5'-triphosphate (GTP) and converts GDP to GTP (known as a “switched on” or in active state). It is the growth promoting stimuli that causes the induction of RAS wherein the exchange of GDP to GTP occurs there by allowing the active state of RAS to interact with and activate other proteins. This activation of RAS provides a signal to the cell to continue to grow and divide.

It's noteworthy to mention, the Intrinsic ability of RAS protein to turn off by switching back to GDP from GTP is very low and for RAS to turn off it requires GTPase-activating proteins (GAPs) which interact with RAS and greatly accelerate the conversion of GTP to GDP. Any mutation in RAS which affects its ability to interact with GAP or to convert GTP back to GDP result in a prolonged activation of the protein and consequently a prolonged and overactive RAS signaling ultimately lead to cancer.

RAS family is further divided in several members such as HRAS; KRAS; DIRAS1; DIRAS2; DIRAS3; ERAS; GEM; MRAS; NKIRAS1; NKIRAS2; NRAS; RALA; RALB; RAP1A; RAP1B; RAP2A; RAP2B; RAP2C; RASD1; RASD2; RASL10A; RASL10B; RASL11A; RASL11B; RASL12; REM1; REM2; RERG; RERGL; RRAD; RRAS however the most notable RAS members associated with cancers are Harvey rat sarcoma viral oncogene homolog (HRAS) Kirsten rat sarcoma viral oncogene homolog (KRAS) and Neuroblastoma rat sarcoma viral oncogene homolog (NRAS).

With the three HRAS, KRAS and NRAS members, majority of mutations of around 25-30 % in tumors are detected in KRAS gene with around 30 % of all human tumors been reported to have some mutation to RAS gene.

Mutation of KRAS gene are more common in pancreatic cancer, lung adenocarcinoma, colorectal cancer, gall bladder cancer, thyroid cancer, and bile duct cancer. KRAS mutations have also been seen in about 25% of patients with NSCLC, and some studies have indicated that KRAS mutations are a negative prognostic factor in patients with NSCLC. Recently, KRAS mutations have been found to confer resistance to epidermal growth factor receptor (EGFR) targeted therapies in colorectal cancer; Understanding the status of KRAS mutation seems to be gaining importance prior to use of tyrosine kinase inhibitors (TKI).

The most common KRAS mutations are found in the P-loop at residue G12 and G13 and at residue Q61 with G12C been a frequent mutation of KRAS gene. G12C mutation have been reported to be around 14-15 % across several cancers with majority been reported in Lung and colon cancer.

Researchers have learned a lot about how cancer genes work. But many cancers are not linked with a specific gene. Cancer likely involves multiple gene mutations. Moreover, some evidence suggests that genes interact with their environment. This further complicates our understanding of the role genes play in cancer. Researchers continue to study how genetic changes affect cancer development. This knowledge has led to improvements in cancer care, including early detection, risk reduction, the use of targeted therapy, and survival.


We believe, Cancer in general have very few options of treatment, especially when the cancer is a result of metastasis and is unresectable. On one end there have been several advancement in options of treatment for example use of chemotherapy either alone or in combination with radiation and/or surgery however on the other side there has been a significant amount of challenges with prognosis especially for the cancers such as the lung cancers, pancreatic cancer, prostate cancer, gastric cancer, endometrial cancer, ovarian cancer, colorectal cancer.

Accordingly, there do exists an unmet medical need for treatments for such cancers and the present invention aims to address the same.

## **SUMMARY OF THE INVENTION**

The present invention relates to compounds of formula (A), or pharmaceutically acceptable salts or compositions and methods of treatment with them, In particular the present invention relates to compounds of formula (A) and their pharmaceutically acceptable salts thereof useful in the treatment of RAS mediated cancer.

In one embodiment of the invention, the substituted naphthyridine compounds represented by structural formula (A)



(A)

or a pharmaceutically acceptable salt, stereoisomer, isotope or prodrug thereof, wherein

$R^a$  at each occurrence is independently selected from hydrogen, hydroxy, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy,  $-C(=O)OR^b$ ,  $-C(=O)R^b$ ,  $-C(=S)R^b$ ,  $-C(=O)NR^bR^c$ ,  $-C(=O)ONR^bR^c$ ,  $-NR^bR^c$ ,  $-NR^b-OR^c$ ,  $-NR^bC(=O)NR^bR^c$ ,  $-NR^bS(=O)R^c$ ,  $-NR^bS(=O)_2R^c$ ,  $-NR^b-OR^c$ ,  $=N-NR^bR^c$ ,  $-NR^bC(=O)OR^c$ ,  $-NR^bC(=O)R^c$ ,  $-NR^bC(=S)R^c$ ,  $-NR^bC(=S)NR^bR^c$ ,  $-SONR^bR^c$ ,  $-SO_2NR^bR^c$ ,  $-OR^b$ ,  $-OR^bC(=O)NR^bR^c$ ,  $-OR^bC(=O)OR^c$ ,  $-OC(=O)R^b$ ,  $-OC(=O)NR^bR^c$ ,  $-R^bNR^cC(=O)R^b$ ,  $-R^bOR^c$ ,  $-R^bC(=O)OR^c$ ,  $-R^bC(=O)NR^bR^c$ ,  $-R^bC(=O)R^c$ ,  $-R^bOC(=O)R^c$ ,  $-SR^b$ ,  $-SOR^c$ ,  $-SO_2R^b$ ,  $-CR^bR^cC(=O)R^b$  or  $-CR^bR^cC(=S)R^z$  or any two  $R^a$  may be joined to form a substituted or unsubstituted saturated or unsaturated 3-6 member ring, which may optionally include heteroatoms which may be same or different and are selected from O, NRa or S or ; any two  $R^a$  attached to the same carbon atom may be joined to form a Oxo ( $C=O$ ), Imino ( $=NR^b$ ),  $C=S(O)_p$ , or substituted or unsubstituted saturated or unsaturated 3-6 member ring, which may optionally include heteroatoms which may be same or different and are selected from O, NRa or S.

A<sub>1</sub> is absent or is independently selected from substituted or unsubstituted C<sub>1-4</sub> alkyl, substituted or unsubstituted C<sub>2-4</sub> alkenyl, substituted or unsubstituted C<sub>2-4</sub> alkynyl, substituted or unsubstituted C<sub>3-10</sub> cycloalkyl, substituted or unsubstituted C<sub>3-10</sub> heterocycloalkyl, -(CR<sup>b</sup>R<sup>c</sup>)<sub>p</sub>-, O-, S-, S(=O)<sub>p</sub>-, C(=O)-, -NR<sup>x</sup>-, -CO-NR<sup>x</sup>- and -NR<sup>x</sup>-CO-.

A<sub>2</sub> is absent or is independently selected from substituted or unsubstituted C<sub>1-4</sub> alkyl, substituted or unsubstituted C<sub>2-4</sub> alkenyl, substituted or unsubstituted C<sub>2-4</sub> alkynyl, substituted or unsubstituted C<sub>3-10</sub> cycloalkyl, substituted or unsubstituted C<sub>3-10</sub> heterocycloalkyl, -(CR<sup>b</sup>R<sup>c</sup>)<sub>p</sub>-, O, S, -S(=O)<sub>p</sub>-, -C(=O)-, -NR<sup>x</sup>-, -CO-NR<sup>x</sup>- and -NR<sup>x</sup>-CO-.

Cy<sup>1</sup> is selected from a cyclic group selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl.

Cy<sup>2</sup> is selected from cyclic group selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl which is optionally substituted by E.

E is a group capable of forming a covalent bond or an “Electrophile” or “electrophilic moiety capable of forming a covalent bond

R at each occurrence is independently selected from CN (Cyano), COOH, CONH<sub>2</sub>, SO<sub>3</sub>H, C(=O)OR<sup>b</sup>, -C(=O)R<sup>b</sup>, -C(=S)R<sup>b</sup>, -C(=O)NR<sup>b</sup>R<sup>c</sup>, -C(=O)ONR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>C(=O)NR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>S(=O)R<sup>c</sup>, -NR<sup>b</sup>S(=O)<sub>2</sub>R<sup>c</sup>, -NR<sup>b</sup>-OR<sup>c</sup>, =N-NR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>C(=O)OR<sup>c</sup>, -NR<sup>b</sup>C(=O)R<sup>c</sup>, -NR<sup>b</sup>C(=S)R<sup>c</sup>, -NR<sup>b</sup>C(=S)NR<sup>b</sup>R<sup>c</sup>, -SONR<sup>b</sup>R<sup>c</sup>, -SO<sub>2</sub>NR<sup>b</sup>R<sup>c</sup>, -OR<sup>b</sup>, -OR<sup>b</sup>C(=O)NR<sup>b</sup>R<sup>c</sup>, -OR<sup>b</sup>C(=O)OR<sup>c</sup>, -OC(=O)R<sup>b</sup>, -OC(=O)NR<sup>b</sup>R<sup>c</sup>, -R<sup>b</sup>NR<sup>c</sup>C(=O)R<sup>b</sup>, -R<sup>b</sup>OR<sup>c</sup>, -R<sup>b</sup>C(=O)OR<sup>c</sup>, -R<sup>b</sup>C(=O)NR<sup>b</sup>R<sup>c</sup>, -R<sup>b</sup>C(=O)R<sup>c</sup>, -R<sup>b</sup>OC(=O)R<sup>c</sup>, -SR<sup>b</sup>, -SOR<sup>c</sup>, -SO<sub>2</sub>R<sup>b</sup>, -CR<sup>b</sup>R<sup>c</sup>C(=O)R<sup>b</sup> or -CR<sup>b</sup>R<sup>c</sup>C(=S)R<sup>z</sup>.

R<sup>1</sup> at each occurrence is independently selected from hydrogen, hydroxy, halogen, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or

unsubstituted heteroarylalkyl,  $C(=O)OR^b$ ,  $-C(=O)R^b$ ,  $-C(=S)R^b$ ,  $-C(=O)NR^bR^c$ ,  $-C(=O)ONR^bR^c$ ,  $-NR^bR^c$ ,  $-NR^bC(=O)NR^bR^c$ ,  $-NR^bS(=O)R^c$ ,  $-NR^bS(=O)_2R^c$ ,  $-NR^b-OR^c$ ,  $=N-NR^bR^c$ ,  $-NR^bC(=O)OR^c$ ,  $-NR^bC(=O)R^c$ ,  $-NR^bC(=S)R^c$ ,  $-NR^bC(=S)NR^bR^c$ ,  $-SONR^bR^c$ ,  $-SO_2NR^bR^c$ ,  $-OR^b$ ,  $-OR^bC(=O)NR^bR^c$ ,  $-OR^bC(=O)OR^c$ ,  $-OC(=O)R^b$ ,  $-OC(=O)NR^bR^c$ ,  $-R^bNR^cC(=O)R^b$ ,  $-R^bOR^c$ ,  $-R^bC(=O)OR^c$ ,  $-R^bC(=O)NR^bR^c$ ,  $-R^bC(=O)R^c$ ,  $-R^bOC(=O)R^c$ ,  $-SR^b$ ,  $-SOR^c$ ,  $-SO_2R^b$ ,  $-CR^bR^cC(=O)R^b$  or  $-CR^bR^cC(=S)R^z$ .

each occurrence of  $R^b$  and  $R^c$  is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic ring, substituted heterocyclalkyl ring, or substituted or unsubstituted amino, or any two of  $R^x$  and  $R^y$  when bound to a common atom may be joined to form (i) a substituted or unsubstituted saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O,  $NR^x$  or S, or (ii) an oxo ( $=O$ ), thio ( $=S$ ) or imino ( $=NR^x$ ) group; and

each occurrence of p is independently 0, 1 or 2.

Further preferred are compounds having the formula **(A)** wherein  $R^a$  is Hydrogen or alkyl

Further preferred are compounds having the formula **(A)** wherein two  $R^a$  attached to same carbon atom form a  $C=O$  (Oxo) group.

Further preferred are compounds having the formula **(A)** wherein  $A_1$  is absent or is  $-CR^bR^c-$ ; where in each of  $R^b$  and  $R^c$  is independently selected from hydrogen, substituted or unsubstituted alkyl.

Further preferred are compounds having the formula **(A)** wherein  $A_1$  is absent or is  $-CR^bR^c-$ ; where in  $R^b$  is independently methyl or ethyl and  $R^c$  is hydrogen.

Further preferred are compounds having the formula **(A)** wherein  $A_2$  is absent or is  $-CR^bR^c-$ ; where in each of  $R^b$  and  $R^c$  is independently selected from hydrogen, substituted or unsubstituted alkyl

Further preferred are compounds having the formula **(A)** wherein  $A_2$  is absent or is  $-CR^bR^c-$ ; where in  $R^b$  is independently methyl or ethyl and  $R^c$  is hydrogen.

Further preferred are compounds having the formula **(A)** wherein  $R^1$  is absent or selected from  $OR^b$ ,  $S-R^b$ ,  $-S(=O)pR^b$ ,  $-C(=O)-R^b$ ,  $-NR^bR^c$ ,  $-CO-NR^bR^c$ - and  $-NR^b-CO-R^c$ ;


Further preferred are compounds having the formula **(A)** wherein  $R^1$  is  $-O-R^b$


Further preferred are compounds having the formula **(A)** wherein  $R^1$  is  $-NR^bR^c$

Further preferred are compounds having the formula **(A)** wherein  $R^1$  is independently selected from, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl.

Further preferred are compounds having the formula **(A)** wherein  $R^1$  is independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl and substituted or unsubstituted heteroaryl

Further preferred are compounds having the formula **(A)** wherein  $R^1$  is independently selected from







Further preferred are compounds having the formula (A) wherein A<sub>1</sub> is absent or -CH<sub>2</sub> or - (C=O)

Further preferred are compounds having the formula (A) wherein Cy<sup>1</sup> is selected from a cyclic group selected from substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl.

Further preferred are compounds having the formula (A) wherein Cy<sup>1</sup> is selected from a cyclic group selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.

Further preferred are compounds having the formula (A) wherein Cy<sup>1</sup> is selected from






Further preferred are compounds having the formula **(A)** wherein Cy<sup>2</sup> is selected from cyclic group selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocyclyl and substituted or unsubstituted heterocyclylalkyl.

Further preferred are compounds having the formula **(A)** wherein Cy<sup>2</sup> is selected from cyclic group selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocyclyl and substituted or unsubstituted heterocyclylalkyl wherein each group is optionally further substituted with group E.

Further preferred are compounds having the formula **(A)** wherein R is Cyano (CN).


Further preferred are compounds having the formula **(A)** wherein A<sub>2</sub> is absent.

Further preferred are compounds having the formula **(A)** wherein Cy<sup>2</sup> is selected from




substituted with E a group capable of forming a covalent bond.


Further preferred are compounds having the formula **(A)** wherein E is selected from




Further preferred are compounds having the formula **(A)** wherein E is selected from




Further preferred are compounds having the formula **(A)** wherein A<sub>2</sub>-Cy<sup>2</sup>-E is selected from



Further preferred are compounds having the formula **(A)** wherein A<sub>2</sub>-Cy<sup>2</sup>-E is selected from



In one embodiment of the invention, the substituted naphthyridine compounds represented by structural formula **(A-I)**



**(A-I)**

or a pharmaceutically acceptable salt, stereoisomer, isotope or prodrug thereof, wherein any and all the variables are the same as defined herein in above for the compound of formula (A).

Further preferred are compounds having the formula (A-1) wherein all the general, specific and/or preferred embodiments are the same as described and/or defined herein in above for the compound of formula (A).










The non-limiting representative compounds of the present invention are as listed herein below and pharmaceutically acceptable salts thereof. The present invention should not be construed to be limited to these compounds.










The non-limiting representative compounds of the present invention are as listed herein below and pharmaceutically acceptable salts thereof. The present invention should not be construed to be limited to these compounds.













1. 1-(4-acryloylpiperazin-1-yl)-3-(1,1-dioxidothiomorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

2. 1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-morpholino-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
3. 1-(4-acryloylpiperazin-1-yl)-3-(2-morpholinoethoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
4. 1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(2-morpholinoethoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
5. 3-(4-acryloylpiperazin-1-yl)-1-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
6. 3-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-1-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
7. 3-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-1-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
8. (S)-1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
9. (S)-1-(4-acryloylpiperazin-1-yl)-6-(3-hydroxynaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
10. (S)-1-(4-(2-fluoroacryloyl)piperazin-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-6-(quinazolin-4-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
11. (S)-6-(8-chloronaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-1-(4-(vinylsulfonyl)piperazin-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
12. 6-(8-chloronaphthalen-1-yl)-1-(4-(2-fluoroacryloyl)-3-methylpiperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
13. 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
14. 1-(((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
15. 1-(((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
16. 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.

17. 1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
18. 1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
19. 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(3-hydroxynaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
20. 1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
21. (S)-1-(4-acryloylpiperazin-1-yl)-6-(isoquinolin-4-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
22. (S)-1-(4-acryloylpiperazin-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-6-(quinolin-8-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
23. 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:
24. 1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
25. 1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
26. 6-(8-chloronaphthalen-1-yl)-1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.
27. 6-(8-chloronaphthalen-1-yl)-1-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
28. 6-(8-chloronaphthalen-1-yl)-1-((R)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
29. 1-(4-acryloylpiperazin-1-yl)-6-benzyl-3-chloro-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile
30. N-(1-(6-benzyl-3-chloro-4-cyano-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperidin-4-yl)acrylamide
31. N-(1-(6-benzyl-4-cyano-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperidin-4-yl)acrylamide


| Examples Structures                                                                 |                                                                                     |                                                                                      |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Ex1                                                                                 | Ex2                                                                                 | Ex3                                                                                  |
|    |    |   |
| E4                                                                                  | Ex5                                                                                 | Ex6                                                                                  |
|   |   |  |
| Ex7                                                                                 | Ex8                                                                                 | Ex9                                                                                  |
|  |  |  |
| Ex10                                                                                | Ex11                                                                                | Ex12                                                                                 |


|                                                                                     |                                                                                     |                                                                                       |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
|    |    |    |
| <b>Ex13</b>                                                                         | <b>Ex14</b>                                                                         | <b>Ex15</b>                                                                           |
|   |   |   |
| <b>Ex16</b>                                                                         | <b>Ex17</b>                                                                         | <b>Ex18</b>                                                                           |
|  |  |  |
| <b>Ex19</b>                                                                         | <b>Ex20</b>                                                                         | <b>Ex21</b>                                                                           |


|                                                                                     |                                                                                     |                                                                                       |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
|    |    |    |
| <b>Ex22</b>                                                                         | <b>Ex23</b>                                                                         | <b>Ex24</b>                                                                           |
|    |    |    |
| <b>Ex25</b>                                                                         | <b>Ex26</b>                                                                         | <b>Ex27</b>                                                                           |
|   |   |   |
| <b>Ex28</b>                                                                         | <b>EX 29</b>                                                                        | <b>Ex 30</b>                                                                          |
|  |  |  |
| <b>EX 31</b>                                                                        |                                                                                     |                                                                                       |





The non-limiting representative compounds of the present invention as listed herein below, and pharmaceutically acceptable salts thereof are











Another embodiment of the invention is a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Yet another embodiment of the invention is a method for treating cancer in a subject in need thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

Without being bound by a particular theory, provided herewith are the compounds that can modulate (e.g., inhibit) one or more members of the KRAS family, for example, one or more of KRAS mutants. More specifically, and without being bound by a particular theory, it is believed that the compounds described herein can bind to KRAS G12 C and function as covalent inhibitor of KRAS G12 C.

As such, in another embodiment, the invention is a method of treating a KRAS mediated disorder in a subject in need thereof, in particular KRAS G12 C mediated disorder comprising administering to the subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

Another embodiment of the invention is use of a compound of the invention for treating cancer or a RAS-mediated disorder, in particular KRAS G12 C mediated disorder in a subject.

Another embodiment of the invention is use of a compound of the invention for the manufacture of a medicament for treating cancer or a RAS mediated disorder, in particular KRAS G12 C mediated disorder in a subject.

Compounds of the present invention, and pharmaceutically acceptable salts and/or compositions thereof, are useful for treating a variety of cancers, such as solid cancer and, more specifically, solid cancers with KRASG12 mutation.

## **DETAILED DESCRIPTION**

A description of example embodiments of the invention follows. Definitions

Compounds of this invention include those described generally above, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical

elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

Unless specified otherwise within this specification, the nomenclature used in this specification generally follows the examples and rules stated in Nomenclature of Organic Chemistry, Sections A, B, C, D, E, F, and H, Pergamon Press, Oxford, 1979, which is incorporated by reference herein for its exemplary chemical structure names and rules on naming chemical structures. Optionally, a name of a compound may be generated using a chemical naming program: ACD/ChemSketch, Version 5.09/September 2001, Advanced Chemistry Development, Inc., Toronto, Canada.

Compounds of the present invention may have asymmetric centers, chiral axes, and chiral planes (e.g., as described in: E. L. Eliel and S. H. Wilen, Stereo-chemistry of Carbon Compounds, John Wiley & Sons, New York, 1994, pages 1119-1190), and occur as racemates, racemic mixtures, and as individual diastereomers or enantiomers, with all possible isomers and mixtures thereof, including optical isomers, being included in the present invention.

As used herein the following definitions shall apply unless otherwise indicated. Further many of the groups defined herein can be optionally substituted. The listing of substituents in the definition is exemplary and is not to be construed to limit the substituents defined elsewhere in the specification.

The term "alkyl", unless otherwise specified, refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, and 1,1-dimethylethyl (t-butyl). The term "C<sub>1-3</sub>alkyl" refers to an alkyl group as defined above having up to 3 carbon atoms. The term "C<sub>1-6</sub>alkyl" refers to an alkyl group as defined above having up to 6 carbon atoms. In appropriate circumstances, the term "alkyl" refers to a hydrocarbon chain radical as mentioned above which is bivalent.

The term "alkenyl", unless otherwise specified, refers to an aliphatic hydrocarbon group containing one or more carbon-carbon double bonds and which may be a straight or branched or

branched chain having about 2 to about 10 carbon atoms, e.g., ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, and 2-butenyl. The term “C<sub>2-6</sub>alkenyl” refers to an alkenyl group as defined above having up to 6 carbon atoms. In appropriate circumstances, the term “alkenyl” refers to a hydrocarbon group as mentioned above which is bivalent.

The term “alkynyl”, unless otherwise specified, refers to a straight or branched chain hydrocarbyl radical having at least one carbon-carbon triple bond, and having in the range of 2 to up to 12 carbon atoms (with radicals having in the range of 2 to up to 10 carbon atoms presently being preferred) e.g., ethynyl, propynyl, and butynyl. The term “C<sub>2-6</sub> alkynyl” refers to an alkynyl group as defined above having up to 6 carbon atoms. In appropriate circumstances, the term “alkynyl” refers to a hydrocarbyl radical as mentioned above which is bivalent.

The term “alkoxy” unless otherwise specified, denotes an alkyl, cycloalkyl, or cycloalkylalkyl group as defined above attached via an oxygen linkage to the rest of the molecule. The term “substituted alkoxy” refers to an alkoxy group where the alkyl constituent is substituted (i.e., -O-(substituted alkyl). For example “alkoxy” refers to the group -O-alkyl, including from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, and cyclohexyloxy. In appropriate circumstances, the term “alkoxy” refers to a group as mentioned above which is bivalent.

The term “cycloalkyl”, unless otherwise specified, denotes a non-aromatic mono or multicyclic ring system of about 3 to 12 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of multicyclic cycloalkyl groups include perhydronaphthyl, adamantyl and norbornyl groups, bridged cyclic groups, and spirobicyclic groups, e.g., spiro (4,4) non-2-yl. The term “C<sub>3-6</sub> cycloalkyl” refers to a cycloalkyl group as defined above having up to 6 carbon atoms.

The term “cycloalkylalkyl”, unless otherwise specified, refers to a cyclic ring-containing radical containing in the range of about 3 up to 8 carbon atoms directly attached to an alkyl group which is then attached to the main structure at any carbon from the alkyl group, such as cyclopropylmethyl, cyclobutylethyl, and cyclopentylethyl.

The term “cycloalkenyl”, unless otherwise specified, refers to cyclic ring-containing radicals containing in the range of about 3 up to 8 carbon atoms with at least one carbon-carbon double

bond such as cyclopropenyl, cyclobutenyl, and cyclopentenyl. The term “cycloalkenylalkyl” refers to a cycloalkenyl group directly attached to an alkyl group which is then attached to the main structure at any carbon from the alkyl group.

The term “aryl”, unless otherwise specified, refers to aromatic radicals having in the range of 6 up to 20 carbon atoms such as phenyl, naphthyl, tetrahydronaphthyl, indanyl, and biphenyl.

The term “arylalkyl”, unless otherwise specified, refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g.,  $-\text{CH}_2\text{C}_6\text{H}_5$  and  $-\text{C}_2\text{H}_5\text{C}_6\text{H}_5$ .

The term “heterocyclic ring”, unless otherwise specified, refers to a non-aromatic 3 to 15 member ring radical which consists of carbon atoms and at least one heteroatom selected from nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclic ring radical may be a mono-, bi-, tri- or tetracyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized. The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom.

The term “heterocyclyl”, unless otherwise specified, refers to a heterocyclic ring radical as defined above. The heterocyclyl ring radical may be attached to the main structure at any heteroatom or carbon atom.

The term “heterocyclylalkyl”, unless otherwise specified, refers to a heterocyclic ring radical as defined above directly bonded to an alkyl group. The heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group. Examples of such heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazoliny, imidazolidiny, isothiazolidiny, isoxazolidiny, morpholiny, octahydroindolyl, octahydroisoindolyl, 2-oxopiperaziny, 2-oxopiperidiny, 2-oxopyrrolidiny, oxazolidiny, piperidiny, piperaziny, 4-piperidonyl, pyrrolidiny, pyrazolidiny, quinuclidiny, thiazolidiny, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholiny, thiamorpholiny, 1-oxo-thiomorpholiny, and 1,1-dioxo-thiomorpholiny.

The term “heteroaryl”, unless otherwise specified, refers to an optionally substituted 5 to 14 member aromatic ring having one or more heteroatoms selected from N, O, and S as ring atoms. The heteroaryl may be a mono-, bi- or tricyclic ring system. Examples of such “heterocyclic ring” or “heteroaryl” radicals include, but are not limited to, oxazolyl, thiazolyl, imidazolyl, pyrrolyl,

furanyl, pyridinyl, pyrimidinyl, pyrazinyl, benzofuranyl, indolyl, benzothiazolyl, benzoxazolyl, carbazolyl, quinolyl, isoquinolyl, azetidyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolyl, dioxolanyl, indolizyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, tetrazolyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, pyrrolidinyl, pyridazinyl, oxazolyl, oxazolidinyl, triazolyl, indanyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, isoindolyl, indolyl, isoindolyl, octahydroindolyl, octahydroisoindolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, dioxaphospholanyl, oxadiazolyl, chromanyl, and isochromanyl. The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom. The term “substituted heteroaryl” also includes ring systems substituted with one or more oxide (-O-) substituents, such as pyridinyl N-oxides.

The term “heteroarylalkyl”, unless otherwise specified, refers to a heteroaryl ring radical as defined above directly bonded to an alkyl group. The heteroarylalkyl radical may be attached to the main structure at any carbon atom from alkyl group.

The term “cyclic ring” refers to a cyclic ring containing 3 to 10 carbon atoms.

The term “substituted” unless otherwise specified, refers to substitution with any one or any combination of the following substituents which may be the same or different and are independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (=O), thio (=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted heterocyclalkyl ring, substituted or unsubstituted guanidine,  $-COOR^x$ ,  $-C(O)R^x$ ,  $-C(S)R^x$ ,  $-C(O)NR^xR^y$ ,  $-C(O)ONR^xR^y$ ,  $-NR^yR^z$ ,  $-NR^xCONR^yR^z$ ,  $-N(R^x)SOR^y$ ,  $-N(R^x)SO_2R^y$ ,  $-(=N-N(R^x)R^y)$ ,  $-NR^xC(O)OR^y$ ,  $-NR^xR^y$ ,  $-NR^xC(O)R^y$ ,  $-NR^xC(S)R^y$ ,  $-NR^xC(S)NR^yR^z$ ,  $-SONR^xR^y$ ,  $-SO_2NR^xR^y$ ,  $-OR^x$ ,  $-OR^xC(O)NR^yR^z$ ,  $-OR^xC(O)OR^y$ ,  $-OC(O)R^x$ ,  $-OC(O)NR^xR^y$ ,  $-R^xNR^yC(O)R^z$ ,  $-R^xOR^y$ , -

$R^x C(O)OR^y$ ,  $-R^x C(O)NR^yR^z$ ,  $-R^x C(O)R^x$ ,  $-R^x OC(O)R^y$ ,  $-SR^x$ ,  $-SOR^x$ ,  $-SO_2R^x$ , and  $-ONO_2$ , wherein  $R^x$ ,  $R^y$  and  $R^z$  in each of the above groups can be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, or substituted heterocyclalkyl ring, or any two of  $R^x$ ,  $R^y$  and  $R^z$  may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 membered ring, which may optionally include heteroatoms which may be the same or different and are selected from O,  $NR^x$  (e.g.,  $R^x$  can be hydrogen or  $C_{1-6}$  alkyl) or S. Substitution or the combinations of substituents envisioned by this invention are preferably those that result in the formation of a stable or chemically feasible compound. The term stable as used herein refers to the compounds or the structure that are not substantially altered when subjected to conditions to allow for their production, detection and preferably their recovery, purification and incorporation into a pharmaceutical composition. The substituents in the aforementioned "substituted" groups cannot be further substituted. For example, when the substituent on "substituted alkyl" is "substituted aryl", the substituent on "substituted aryl" cannot be "substituted alkenyl".

The term "halo", "halide", or, alternatively, "halogen" means fluoro, chloro, bromo or iodo.

The terms "haloalkyl," "haloalkenyl," "haloalkynyl" and "haloalkoxy" include alkyl, alkenyl, alkynyl and alkoxy structures that are substituted with one or more halo groups or with combinations thereof. For example, the terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine.

The term "protecting group" or "PG" refers to a substituent that is employed to block or protect a particular functionality. Other functional groups on the compound may remain reactive. For example, an "amino-protecting group" is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include, but are not limited to, acetyl, trifluoroacetyl, tert-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a "hydroxy-protecting group" refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable hydroxy-protecting groups include, but are not limited to, acetyl and silyl. A "carboxy-protecting

group" refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Suitable carboxy-protecting groups include, but are not limited to,  $-\text{CH}_2\text{CH}_2\text{SO}_2\text{Ph}$ , cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2-(diphenylphosphino)-ethyl, and nitroethyl. For a general description of protecting groups and their use, see T. W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, New York, 1991.

Certain of the compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present chemical entities, pharmaceutical compositions and methods are meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Non-limiting examples of intermediate mixtures include a mixture of isomers in a ratio of 10:90, 13:87, 17:83, 20:80, or 22:78. Optically active (R)- and (S)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.

The term "tautomers" refers to compounds, which are characterized by relatively easy interconversion of isomeric forms in equilibrium. These isomers are intended to be covered by this invention. "Tautomers" are structurally distinct isomers that interconvert by tautomerization. "Tautomerization" is a form of isomerization and includes prototropic or proton-shift tautomerization, which is considered a subset of acid-base chemistry. "Prototropic tautomerization" or "proton-shift tautomerization" involves the migration of a proton accompanied by changes in bond order, often the interchange of a single bond with an adjacent double bond. Where tautomerization is possible (e.g. in solution), a chemical equilibrium of tautomers can be reached. An example of tautomerization is keto-enol tautomerization. A specific example of keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. A specific example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4(1H)-one tautomers.

Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for

example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.

Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds produced by the replacement of a hydrogen with deuterium or tritium, or of a carbon with a  $^3\text{C}$ -or  $^{14}\text{C}$ -enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention. For example, in the case of variable R, the (C<sub>1</sub>-C<sub>4</sub>) alkyl or the -O-(C<sub>1</sub>-C<sub>4</sub>) alkyl can be suitably deuterated (e.g., -CD<sub>3</sub>, -OCD<sub>3</sub>).

The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( $^3\text{H}$ ), iodine-125 ( $^{125}\text{I}$ ) or carbon-14 ( $^{14}\text{C}$ ). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

The term "stereoisomers" is a general term for all isomers of an individual molecule that differ only in the orientation of their atoms in space. It includes mirror image isomers (enantiomers), geometric (cis/trans) isomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).

"Electrophile" or "electrophilic moiety" is any moiety capable of reacting with a nucleophile (e.g., a moiety having a lone pair of electrons, a negative charge, a partial negative charge and/or an excess of electrons, for example a —SH group). Electrophiles typically are electron poor or comprise atoms which are electron poor. In certain embodiments an electrophile contains a positive charge or partial positive charge, has a resonance structure which contains a positive charge or partial positive charge or is a moiety in which delocalization or polarization of electrons results in one or more atom which contains a positive charge or partial positive charge. In some embodiments, the electrophiles comprise conjugated double bonds, for example an  $\alpha,\beta$ -unsaturated carbonyl or  $\alpha,\beta$ -unsaturated thiocarbonyl compound.

A "leaving group or atom" (Lg or lg) is any group or atom that will, under the reaction conditions, cleave from the starting material, thus promoting reaction at a specified site. Suitable examples of such groups unless otherwise specified are halogen atoms and mesyloxy, p-nitrobenzensulphonyloxy and tosyloxy groups.

"Prodrug" is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound described herein (e.g., compound of structure (I)). Thus, the term "prodrug" refers to a precursor of a biologically active compound that is pharmaceutically acceptable. In some aspects, a prodrug is inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., *Design of Prodrugs* (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in *Bioreversible Carriers in Drug Design*, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, Prodrug design is discussed generally in Hardma, et al. (Eds.), *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 9th ed., pp. 11-16 (1996) all of which are incorporated in full by reference herein. The term "prodrug" is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject. Prodrugs of an active compound, as described herein, are typically prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of a hydroxy functional group, or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound and the like.

In some embodiments, prodrugs include compounds of structure (I) having a phosphate, phosphoalkoxy, ester or boronic ester substituent. Without being bound by theory, it is believed that such substituents are converted to a hydroxyl group under physiological conditions. Accordingly, embodiments include any of the compounds disclosed herein, wherein a hydroxyl

group has been replaced with a phosphate, phosphoalkoxy, ester or boronic ester group, for example a phosphate or phosphoalkoxy group. For example, in some embodiments a hydroxyl group on the R<sup>1</sup> moiety is replaced with a phosphate, phosphoalkoxy, ester or boronic ester group, for example a phosphate or alkoxy phosphate group.

The term "ester" refers to a compound, which is formed by reaction between an acid and an alcohol with elimination of water. An ester can be represented by the general formula RCOOR'.

These prodrugs and esters are intended to be covered within the scope of this invention.

Additionally, the instant invention also includes the compounds which differ only in the presence of one or more isotopically enriched atoms for example replacement of hydrogen with deuterium or tritium, or the replacement of a carbon by <sup>13</sup>C- or <sup>14</sup>C-enriched carbon.

When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included.

The term "about" when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range may vary from, for example, between 1% and 15% of the stated number or numerical range.

The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") includes those embodiments, for example, an embodiment of any composition of matter, composition, method, or process, or the like, that "consist of" or "consist essentially of" the described features.

The following abbreviations and terms have the indicated meanings throughout; Abbreviations used herein have their conventional meaning within the chemical and biological arts.

The term "cell proliferation" refers to a phenomenon by which the cell number has changed as a result of division. This term also encompasses cell growth by which the cell morphology has changed (e.g., increased in size) consistent with a proliferative signal.

The term "co-administration," "administered in combination with," and their grammatical equivalents, as used herein, encompasses administration of two or more agents to an animal so that both agents and/or their metabolites are present in the animal at the same time. Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present.

The term "effective amount" or "therapeutically effective amount" refers to that amount of a compound described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below. The therapeutically effective amount may vary depending upon the intended application (*in vitro* or *in vivo*), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g. reduction of platelet adhesion and/or cell migration. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried. In one embodiment, the amount of compound administered ranges from about 0.1 mg to 5 g, from about 1 mg to 2.0 g, from about 100 mg to 1.5 g, from about 200 mg to 1.5 g, from about 400 mg to 1.5 g, and from about 400 mg to 1.0 g.

As used herein, "treatment," "treating," or "ameliorating" refers to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. In addition a therapeutic benefit is also achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For prophylactic benefit, the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made. These terms are used interchangeably.

A "therapeutic effect," as that term is used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.

As used herein, an amount of a compound effective to treat a disorder, or a "therapeutically effective amount" refers to an amount of the compound which is effective, upon single or multiple

dose administration to a subject or a cell, in curing, alleviating, relieving or improving one or more symptoms of a disorder.

As used herein, an amount of a compound effective to prevent a disorder, or a "prophylactically effective amount" of the compound refers to an amount effective, upon single- or multiple-dose administration to the subject, in preventing or delaying the onset or recurrence of a disorder or one or more symptoms of the disorder.

As used herein, the term "subject" or "patient" is intended to include human and non-human animals. Exemplary human subjects include a human patient having a disorder, e.g., a disorder described herein or a normal subject. The term "non-human animals" of the invention includes all vertebrates, e.g., non-mammals (such as chickens, amphibians, reptiles) and mammals, such as non-human primates, domesticated and/or agriculturally useful animals, e.g., sheep, cow, pig, etc., and companion animals (dog, cat, horse, etc.).

The methods described herein can be useful in both human therapeutics and veterinary applications (e.g., dogs, cats, cows, sheep, pigs, horses, goats, chickens, turkeys, ducks, and geese).

In some embodiments, the patient is a mammal, and in some embodiments, the patient is human.

"Radiation therapy" means exposing a patient, using routine methods and compositions known to the practitioner, to radiation emitters such as alpha-particle emitting radionuclides (e.g., actinium and thorium radionuclides), low linear energy transfer (LET) radiation emitters (i.e. beta emitters), conversion electron emitters (e.g. strontium-89 and samarium- 153-EDTMP), or high-energy radiation, including without limitation x-rays, gamma rays, and neutrons.

The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes, but is not limited to, any and all, a non-toxic solvent, dispersant, excipient, adjuvant, fillers, salts, disintegrants, binders, lubricants, glidants, wetting agents, controlled release matrices, colorants/flavoring, carriers, buffers, stabilizers, solubilizers, or other material and combinations thereof which is mixed with the active ingredient in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of being administered to a patient. One example of such a carrier is pharmaceutically acceptable oil typically used for parenteral administration. Pharmaceutically acceptable carriers are well known in the art.

It is understood that substituents and substitution patterns on the compounds of the invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable

and that can be readily synthesized by techniques known in the art, as well as those methods set forth below. In general, the term "substituted," whether preceded by the term "optionally" or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted group" can have a suitable substituent at each substitutable position of the group and, when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position. Alternatively, an "optionally substituted group" can be unsubstituted.

Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. If a substituent is itself substituted with more than one group, it is understood that these multiple groups can be on the same carbon atom or on different carbon atoms, as long as a stable structure results. The term "stable," as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 1977, 66, 1-19, the relevant teachings of which are incorporated herein by reference in their entirety. Pharmaceutically acceptable salts of the compounds of this invention include salts derived from suitable inorganic and organic acids and bases that are compatible with the treatment of patients.

Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable acid addition salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,

formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

In some embodiments, exemplary inorganic acids which form suitable salts include, but are not limited thereto, hydrochloric, hydrobromic, sulfuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include the mono-, di- and tricarboxylic acids. Illustrative of such acids are, for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2 phenoxybenzoic, p-toluenesulfonic acid and other sulfonic acids such as methanesulfonic acid and 2-hydroxyethanesulfonic acid. Either the mono- or di-acid salts can be formed, or such salts can exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of these compounds are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.

In some embodiments, acid addition salts of the compounds of formula A are most suitably formed from pharmaceutically acceptable acids, and include, for example, those formed with inorganic acids, e.g., hydrochloric, sulfuric or phosphoric acids and organic acids e.g. succinic, maleic, acetic or fumaric acid.

Other non-pharmaceutically acceptable salts, e.g., oxalates can be used, for example, in the isolation of compounds of formula I for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt. Also included within the scope of the invention are base addition salts (such as sodium, potassium and ammonium salts), solvates and hydrates of compounds of the invention. The conversion of a given compound salt to a desired compound salt is achieved by applying standard techniques, well known to one skilled in the art.

An “anti-cancer agent”, “anti-tumor agent” or “chemotherapeutic agent” refers to any agent useful in the treatment of a neoplastic condition. One class of anti-cancer agents comprises chemotherapeutic agents. “Chemotherapy” means the administration of one or more

chemotherapeutic drugs and/or other agents to a cancer patient by various methods, including intravenous, oral, intramuscular, intraperitoneal, intravesical, subcutaneous, transdermal, buccal, or inhalation or in the form of a suppository. The term “cell proliferation” refers to a phenomenon by which the cell number has changed as a result of division. This term also encompasses cell growth by which the cell morphology has changed (e.g., increased in size) consistent with a proliferative signal.

The term “selective inhibition” or “selectively inhibit” refers to a biologically active agent refers to the agent's ability to preferentially reduce the target signaling activity as compared to off-target signaling activity, via direct or indirect interaction with the target.

“Optional” or “optionally” means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted aryl” means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.

A “pharmaceutical composition” refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients thereof.

When introducing elements disclosed herein, the articles “a,” “an,” “the,” and “said” are intended to mean that there are one or more of the elements. The terms “comprising,” “having” and “including” are intended to be open-ended and mean that there may be additional elements other than the listed elements.

For example, provided herein are methods of treating various cancers in mammals (including humans and non-humans), comprising administering to a patient in need thereof a compound of the invention, or a pharmaceutically acceptable salt thereof. Such cancers include hematologic malignancies (leukemias, lymphomas, myelomas, myelodysplastic and myeloproliferative syndromes) and solid tumors (carcinomas such as oral, gall bladder, prostate, breast, lung, colon, pancreatic, renal, ovarian as well as soft tissue and osteo sarcomas, and stromal tumors). Breast cancer (BC) can include basal-like breast cancer (BLBC), triple negative breast cancer (TNBC) and breast cancer that is both BLBC and TNBC. In addition, breast cancer can include invasive or non-invasive ductal or lobular carcinoma, tubular, medullary, mucinous, papillary, cribriform

carcinoma of the breast, male breast cancer, recurrent or metastatic breast cancer, phyllodes tumor of the breast and Paget's disease of the nipple. In some embodiments, the present invention provides a method of treating lymphoma, specifically, mantle cell lymphoma.

In further aspects, the present invention provides a use of a compound of the invention, of a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of cancer. In some embodiments, the present invention provides a use of a compound of the invention in the manufacture of a medicament for the treatment of any of cancer and/or neoplastic disorders.

A compound or composition described herein can be used to treat a neoplastic disorder. A "neoplastic disorder" is a disease or disorder characterized by cells that have the capacity for autonomous growth or replication, e.g., an abnormal state or condition characterized by proliferative cell growth. Exemplary neoplastic disorders include: carcinoma, sarcoma, metastatic disorders, e.g., tumors arising from prostate, brain, bone, colon, lung, breast, ovarian, and liver origin, hematopoietic neoplastic disorders, e.g., leukemias, lymphomas, myeloma and other malignant plasma cell disorders, and metastatic tumors. Prevalent cancers include: breast, prostate, colon, lung, liver, and pancreatic cancers. Treatment with the compound can be in an amount effective to ameliorate at least one symptom of the neoplastic disorder, e.g., reduced cell proliferation, reduced tumor mass, etc.

The disclosed methods are useful in the prevention and treatment of cancer, including for example, solid tumors, soft tissue tumors, and metastases thereof, as well as in familial cancer syndromes such as Li Fraumeni Syndrome, Familial Breast-Ovarian Cancer (BRCA1 or BRCA2 mutations) Syndromes, and others. The disclosed methods are also useful in treating non-solid cancers. Exemplary solid tumors include malignancies (e.g., sarcomas, adenocarcinomas, and carcinomas) of the various organ systems, such as those of lung, breast, lymphoid, gastrointestinal (e.g., colon), and genitourinary (e.g., renal, urothelial, or testicular tumors) tracts, pharynx, prostate, and ovary. Exemplary adenocarcinomas include colorectal cancers, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, and cancer of the small intestine.

Exemplary cancers described by the National Cancer Institute include: Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Childhood; Acute Myeloid Leukemia, Adult; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; AIDS-Related Lymphoma; AIDS-Related Malignancies; Anal Cancer; Astrocytoma, Childhood

Cerebellar; Astrocytoma, Childhood Cerebral; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bladder Cancer, Childhood; Bone Cancer, Osteosarcoma/Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Cerebellar Astrocytoma, Childhood; Brain Tumor, Cerebral Astrocytoma/Malignant Glioma, Childhood; Brain Tumor, Ependymoma, Childhood; Brain Tumor, Medulloblastoma, Childhood; Brain Tumor, Supratentorial Primitive Neuroectodermal Tumors, Childhood; Brain Tumor, Visual Pathway and Hypothalamic Glioma, Childhood; Brain Tumor, Childhood (Other); Breast Cancer; Breast Cancer and Pregnancy; Breast Cancer, Childhood; Breast Cancer, Male; Bronchial Adenomas/Carcinoids, Childhood; Carcinoid Tumor, Childhood; Carcinoid Tumor, Gastrointestinal; Carcinoma, Adrenocortical; Carcinoma, Islet Cell; Carcinoma of Unknown Primary; Central Nervous System Lymphoma, Primary; Cerebellar Astrocytoma, Childhood; Cerebral Astrocytoma/Malignant Glioma, Childhood; Cervical Cancer; Childhood Cancers; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Clear Cell Sarcoma of Tendon Sheaths; Colon Cancer; Colorectal Cancer, Childhood; Cutaneous T-Cell Lymphoma; Endometrial Cancer; Ependymoma, Childhood; Epithelial Cancer, Ovarian; Esophageal Cancer; Esophageal Cancer, Childhood; Ewing's Family of Tumors; Extracranial Germ Cell Tumor, Childhood; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastric (Stomach) Cancer, Childhood; Gastrointestinal Carcinoid Tumor; Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma, Childhood Brain Stem; Glioma, Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer, Adult (Primary); Hepatocellular (Liver) Cancer, Childhood (Primary); Hodgkin's Lymphoma, Adult; Hodgkin's Lymphoma, Childhood; Hodgkin's Lymphoma During Pregnancy; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma, Childhood; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas); Kaposi's Sarcoma; Kidney Cancer; Laryngeal Cancer; Laryngeal Cancer, Childhood; Leukemia, Acute Lymphoblastic, Adult; Leukemia, Acute Lymphoblastic, Childhood; Leukemia, Acute Myeloid, Adult; Leukemia, Acute Myeloid, Childhood; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer, Adult (Primary); Liver Cancer, Childhood (Primary); Lung Cancer, Non-Small Cell; Lung Cancer, Small

Cell; Lymphoblastic Leukemia, Adult Acute; Lymphoblastic Leukemia, Childhood Acute; Lymphocytic Leukemia, Chronic; Lymphoma, AIDS- Related; Lymphoma, Central Nervous System (Primary); Lymphoma, Cutaneous T-Cell; Lymphoma, Hodgkin's, Adult; Lymphoma, Hodgkin's, Childhood; Lymphoma, Hodgkin's During Pregnancy; Lymphoma, Non-Hodgkin's, Adult; Lymphoma, Non- Hodgkin's, Childhood; Lymphoma, Non-Hodgkin's During Pregnancy; Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenstrom's; Male Breast Cancer; Malignant Mesothelioma, Adult; Malignant Mesothelioma, Childhood; Malignant Thymoma; Mantle Cell Lymphoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular; Merkel Cell Carcinoma; Mesothelioma, Malignant; Metastatic Squamous Neck Cancer with Occult Primary; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplastic Syndromes; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Nasopharyngeal Cancer, Childhood; Neuroblastoma; Non-Hodgkin's Lymphoma, Adult; Non-Hodgkin's Lymphoma, Childhood; Non- Hodgkin's Lymphoma During Pregnancy; Non-Small Cell Lung Cancer; Oral Cancer, Childhood; Oral Cavity and Lip Cancer; Oropharyngeal Cancer; Osteosarcoma/Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer, Childhood; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Childhood; Pancreatic Cancer, Islet Cell; Paranasal Sinus and Nasal Cavity Cancer; Parathyroid Cancer; Penile Cancer; Pheochromocytoma; Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood; Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma; Pregnancy and Breast Cancer; Pregnancy and Hodgkin's Lymphoma; Pregnancy and Non-Hodgkin's Lymphoma; Primary Central Nervous System Lymphoma; Primary Liver Cancer, Adult; Primary Liver Cancer, Childhood; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Cell Cancer, Childhood; Renal Pelvis and Ureter, Transitional Cell Cancer; Retinoblastoma; Rhabdomyosarcoma, Childhood; Salivary Gland Cancer; Salivary Gland Cancer, Childhood; Sarcoma, Ewing's Family of Tumors; Sarcoma, Kaposi's; Sarcoma (Osteosarcoma)/Malignant Fibrous Histiocytoma of Bone; Sarcoma, Rhabdomyosarcoma, Childhood; Sarcoma, Soft Tissue, Adult; Sarcoma, Soft Tissue, Childhood; Sezary Syndrome; Skin Cancer; Skin Cancer, Childhood; Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine

Cancer; Soft Tissue Sarcoma, Adult; Soft Tissue Sarcoma, Childhood; Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Stomach (Gastric) Cancer, Childhood; Supratentorial Primitive Neuroectodermal Tumors, Childhood; T- Cell Lymphoma, Cutaneous; Testicular Cancer; Thymoma, Childhood; Thymoma, Malignant; Thyroid Cancer; Thyroid Cancer, Childhood; Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational; Unknown Primary Site, Cancer of, Childhood; Unusual Cancers of Childhood; Ureter and Renal Pelvis, Transitional Cell Cancer; Urethral Cancer; Uterine Sarcoma; Vaginal Cancer; Visual Pathway and Hypothalamic Glioma, Childhood; Vulvar Cancer; Waldenstrom's Macro globulinemia; and Wilms' Tumor. Further exemplary cancers include diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and serous and endometrioid cancer. Yet a further exemplary cancer is alveolar soft part sarcoma.

Further exemplary cancers include diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Yet further exemplary cancers include endocervical cancer, B cell ALL, T-cell ALL, B- or T-cell lymphoma, mast cell cancer, glioblastoma, neuroblastoma, follicular lymphoma and Richter's syndrome. Yet further exemplary cancers include glioma.

Metastases of the aforementioned cancers can also be treated or prevented in accordance with the methods described herein.

#### Combination therapies

In some embodiments, a compound described herein is administered together with an additional "second" therapeutic agent or treatment. The choice of second therapeutic agent may be made from any agent that is typically used in a monotherapy to treat the indicated disease or condition. As used herein, the term "administered together" and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a compound of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising a compound of any of the formulas described herein, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.


In one embodiment of the invention, where a second therapeutic agent is administered to a subject, the effective amount of the compound of this invention is less than its effective amount would be where the second therapeutic agent is not administered. In another embodiment, the

effective amount of the second therapeutic agent is less than its effective amount would be where the compound of this invention is not administered. In this way, undesired side effects associated with high doses of either agent may be minimized. Other potential advantages (including without limitation improved dosing regimens and/or reduced drug cost) will be apparent to those of skill in the art. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.

### Process Of Preparation Of The Compound Of The Invention


The instant compounds of the present invention may be prepared by the following general process. The process provided herein can similarly be applied to synthesize all possible variation of the compound of the invention, and in particular compounds of formulas (A) as provided herein above with all intended modification or without any modification. Unless otherwise indicated, the variables such as R, R<sup>a</sup>, R<sup>1</sup>, A<sub>1</sub>, A<sub>2</sub>, Cy<sup>1</sup>, Cy<sup>2</sup> and E used here in various intermediates or compounds of formulas are to be constructed to be the variables defined herein above in relation to compound of the invention and in particular to the compound of formula (A).

**Synthetic Scheme A:** This schematic representation of scheme aims to provide a possible route for the preparation of a compound of formula (A)




Intermediate of formula (A1) where in Pg is a suitable protecting group when reacted with an intermediate of formula  $R-CH_2-CONH_2$ , using a suitable base or reagent to get an intermediate of formula (A2). Intermediate of formula (A2) can then be subjected to chloration using  $POCl_3$  to get an intermediate of formula (A3) which on reacting with an intermediate of formula  $Lg-A_2-Cy^2$  wherein Lg is a good leaving group using a suitable base to get an intermediate of formula (A4). Intermediate of formula (A4) is in turn can be coupled with an intermediate of formula  $Lg-R^1$  wherein Lg is a good leaving group, using a suitable base to get an Intermediate of formula (A5). Intermediate of formula (A5). Intermediate (A5) can then be de-protected followed by coupling with a group  $Lg-A_1-Cy^1$  under suitable conditions such as bukward coupling or other suitable N-Alkylation or N-Arylation to provide a desired compound of formula (A)


**A. Scheme of Example 1 provides for illustrative use of scheme A as below**



**B. Scheme below provides for yet another illustrative use of scheme A to prepare a compound of invention**



**C. Scheme below provides for yet another illustrative use of scheme A to prepare a compound of invention**



## Experimental Details

### Part-A : Preparation of Intermediates

**Intermediate 1 : ( ethyl 1-benzyl-3-oxopiperidine-4-carboxylate)** In a reaction flask, (26 g, 80.00 mmol) of ethyl 4-(benzyl(2-methoxy-2-oxoethyl)amino)butanoate and (11 g, 160 mmol) of sodium ethoxide were added to 260 mL of toluene, heating reaction reflux 5h, TLC monitoring of raw materials completely complete reaction, the reaction solution cooled to room temperature, add water 150mL, with ethyl acetate 250 mL extraction reaction 2 times, the organic phase. The organic phase was washed with an amount of saturated brine solution and the organic phase was distilled off to give 14 g of oily compound. MS (m/z): 262.24  $[M+H]^+$ .

**Intermediate 2: 6-benzyl-1,3-dioxo-1,2,3,4,5,6,7,8-octahydro-2,6-naphthyridine-4-carbonitrile** In the 2-necked flask equipped with a mechanical stirrer, and a condenser was placed above intermediate (14 g, 50.00 mmol) in methanol (105 ml). The cyanoacetamide (4.5 g, 50.00 mmol) was added followed by addition of a potassium hydroxide solution in methanol (3.94 g, 50 mmol of KOH in 50 mL MeOH). The resulting mixture was stirred and heated to reflux. The product was started to form as a white solid after few minutes. The reaction mixture was refluxed for 4 hr and cooled to room temperature overnight. The white solid was collected and filter cake was washed with methanol (300 mL). The white solid was transferred into a 1L single necked flask equipped with a mechanical stirrer with the aid of warm water (250 ml of 55° C.). The resulting mixture was stirred and acidified to pH=6 with acetic acid. After 1 hr stirring, the white solid was

collected, washed with water, pressed well with a rubber dam and air dried in a hood overnight to give 10 g of the title compound. MS (m/z): 282.20  $[M+H]^+$ .

**Intermediate 3: 6-benzyl-1,3-dichloro-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile**

**Method I:** Intermediate 2 (5 g, 10.00 mmol) and phosphorus oxychloride (20 mL). The vessel was sealed and heated at 180° C. for 4 hr, reaction mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (500 ml) and added into a 1L 3-necked flask equipped with a mechanical stirrer containing ice (about 45 g). The resulting mixture was basified to pH=9-10 by adding approximately 50 mL 20percent aqueous sodium hydroxide solution. During this addition more ice was added to keep internal temperature under 30° C. The mixture was stirred for 15 min and then was filtered to remove a gel type particle. The organic layer was separated, washed with brine (50 mL), filtered through filter paper and concentrated under reduced pressure. (1.5 g) as an oil which solidified on standing. MS (m/z): 318.20  $[M+H]^+$ .

**Method II:** Intermediate 2 (20 gm g, 0.071 mol, salt free), tetramethylammonium chloride (9.3 g, 0.085 mol) and phosphorus oxychloride (67 mL, 0.71 mol) were taken in a 500 mL sealed vessel and heated at 120° C for 8hrs. The reaction was cooled to RT, slowly open the vessel. Reaction mixture was slowly poured in to ice and stirred the reaction mixture for 30 min. Then the saturated solution of NaOH was added slowly to the cold and diluted RM to turn it alkaline (pH = 8-10) and maintenance the temperature below 40 °C. The brown colored solid was formed and it was filtrated over the filtration flask and dried over 2 hr we got **Intermediate 3** (14 g.). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 7.36-7.30 (m, 5H), 3.81 (s, 2H), 3.75 (s, 2H), 2.84-2.82 (d, 2H, *J*=5.2 Hz), 2.80-2.78 (d, 2H, *J*=5.2 Hz). MS (m/z): 318.20  $[M+H]^+$ .

**Intermediates 4A: benzyl-4-cyano-5,6,7,8-tetrahydro-2,6-naphthyridine-1,3-diyl bis(trifluoromethanesulfonate):** Intermediate 2 (5 gram, 0.01 mole) and 2,6 lutidine(5.9 gram, 0.055 mole) were dissolved in DCM (200 ml) and cooled to 0°C under nitrogen atmosphere, Triflic Anhydride (10 gram, 0.035) in DCM(25 ml) was then added dropwise over a period of 20 mins. The reaction was allowed to gradually warm to 25 °C over a period of 2 hr. The reaction mixture was concentrated in vacuo and the resulting oil was dissolved in ethyl acetate and the organic layer was washed thrice with 10 % KHSO<sub>4</sub> followed by brine and the organic layer was concentrated in vacuo. The resulting solid was purified by column chromatography (100-200 mesh silica gel,

0-40% ethyl acetate -hexane) to get **Intermediate 4** (3.2 gm). <sup>1</sup>H-NMR ( $\delta$  ppm, CDCl<sub>3</sub>, 400 MHz): 7.35(m, 5H), 3.91(s, 2H), 3.79(s, 2H), 2.91(t, 2H), 2.83(m,2H). MS (m/z): 545 [*M*+H]<sup>+</sup>

**Intermediates 5: tert-butyl (1-(6-benzyl-3-chloro-4-cyano-5,6,7,8-tetrahydro-2,6-napht hyridin-1-yl)piperidin-4-yl)carbamate:** tert-butyl piperidin-4-ylcarbamate (0.5 g, 16 mmol) was dissolved in DMF (5 ml), followed by addition of potassium carbonate (0.54 g, 30 mmol) in the reaction mixture and stirred at room temperature for 10 min. Intermediate 3 (0.5 g, 10 mmol) was added in reaction mixture and heated reaction at 80 °C for 20 minutes. The reaction completion was check by TLC, reaction was poured into water and ethyl acetate and separated. The organic layer was dried over sodium sulphate and concentrated under reduced pressure to get oily (0.3 g) compound, was used in next step without analytical data.

**Intermediates 5A: Tert-butyl 4-(6-benzyl-4-cyano-3-(((trifluoromethyl)sulfonyl)oxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate:** To solution of tert-butyl piperazine-1-carboxylate (0.46 gm, 0.001 mol) in THF (30 ml) was added DIPEA (1.2 ml, 0.03 mol) and stirred. Solution of **Intermediate 4A** (1.5 gm, 0.001 mol) in THF (10 ml) was added to the reaction mixture dropwise and stirred at room temperature for 2 hr. Reaction mixture was quenched with water and extracted by ethyl acetate. Separated organic layer, was washed with brine followed by drying over sodium sulphate. Organic layer was concentrated under reduce pressure to get the crude residue which was purified by column chromatography using ethyl acetate: hexane (25 %) to get **Intermediate 5A** (1.25 gm). <sup>1</sup>H-NMR ( $\delta$  ppm, CDCl<sub>3</sub>, 400 MHz): 7.36-7.35 (m, 4H), 7.32-7.30 (m, 1H), 3.82 (s, 2H), 3.72 (s, 2H), 3.52-3.51 (m, 4H), 3.43-3.41(m, 4H), 2.68-2.63 (m, 4H). 582.50 [*M*+H]<sup>+</sup>.

**Intermediates 5B: Tert-butyl 4-(6-benzyl-4-cyano-3-(((trifluoromethyl)sulfonyl)oxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate:** 2-(piperazin-2-yl) acetonitrile (0.920 gm, 0.0073 mol) and DIEPA (1.37 ml, 0.0073 mol) was dissolved in DCM (40 ml) and cooled to 0°C under nitrogen atmosphere. **Intermediates 4A** (2.7 gm, 0.0049 mol) in DCM (10 ml) was added dropwise to the reaction mixture. The reaction was stirred at room temperature for 12 hr. . To the above reaction mixture solution of (BOC)<sub>2</sub>O in DCM (10 ml) was added dropwise at RT and stirred for another 12 hr. The reaction mixture was quenched with water and organic

layer was separated and washed with brine and concentrated in vacuo to give oily residue which was purified by column chromatography (100-200 mesh silica gel) using 30% Ethyl acetate: hexane to get Intermediate 9B as white solid (1.7 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 7.38-7.33 (m, 5H), 4.62-4.60 (m, 1H), 4.06 (bs, 1H), 3.99-3.82 (m, 1H), 3.76-3.67 (m, 5H), 3.35-3.34 (m, 1H), 3.24-3.23 (m, 1H), 2.83-2.71 (m, 5H), 2.58-2.55 (m, 1H), 1.48 (s, 9H), 621.22 [*M*+H]<sup>+</sup>.

**Intermediates 5C: tert-butyl 4-(6-benzyl-3-chloro-4-cyano-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-(cyanomethyl)piperazine-1-carboxylate** 2-(piperazin-2-yl) acetonitrile (29.48 g, 0.23 mol) was added in 4 neck 3 lit RBF, in 1,4-dioxane (1000 ml), followed by addition of DIPEA (144 mL, 0.75 mol) in the above suspension and stirred at 0 °C for 10 min. **Intermediate 3b** (50 g, 0.15 mol) was added to the reaction mixture and stirred at 55 °C for 12 hrs. After formation of new polar spot reaction mixture was cooled to RT and Boc-anhydride (98 mL, 0.45 mol) was added to it and stirred at 55 °C for 2 hrs. After completion of reaction the RM was poured into cold water and extracted with ethyl acetate (1 lit X 2). The organic layer was dried over sodium sulphate and concentrated under reduced pressure to get a crude residue. The crude was purified by column chromatography using 20-50% EtOAc in pet ether as mobile phase. The pure fractions were collected and concentrated under reduced pressure to affords **Intermediate 5C** (40 g) as white solid. <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 7.35-7.34 (m, 4H), 7.31-7.29 (m, 1H), 4.59 (bs, 1H), 3.90 (bs, 1H), 3.83-3.68 (m, 6H), 3.27-3.23 (m, 2H), 2.99-2.92 (m, 1H), 2.81-2.69 (m, 5H), 2.67-2.65 (m, 1H). MS (m/z): 507.2 [*M*+H]<sup>+</sup>.

**Intermediates 5D: tert-butyl 4-(6-benzyl-4-cyano-3-(((trifluoromethyl)sulfonyl)oxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-methylpiperazine-1-carboxylate:** Was prepared using the process as described above for **Intermediate 5A** using 3-methyl piperazine-1-carboxylate (1.21 gm, 0.0065 mmol) and Intermediate 4 (3.0 gm, 0.0055 mol) to get **Intermediate 5D** (2.22 gm). 596.24 [*M*+H]<sup>+</sup>.

**Intermediates 5E: 6-benzyl-4-cyano-1-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl trifluoromethanesulfonate.**

Was prepared using the process as described above for **Intermediate 5A** using 2,6-dimethyl morpholine (1.25 gm, 0.00688 mmol) and **Intermediate 4** (2.5 gm, 0.0045 mol) to get **Intermediates 5E** (1.8 gm). 510.95  $[M+H]^+$ .

**Intermediates 6: 1-(4-aminopiperidin-1-yl)-6-benzyl-3-chloro-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile :**

To a solution of Intermediate 5 (0.5 g) was dissolved in dioxane :HCl (10 ml), stirred reaction mixture for 1 hr at 0°C. After completion of the reaction, it was evaporated under reduced pressure to get oily compound, was dissolved in di ethyl ether to get solid, we used next step directly without analytical data.

**Intermediates 6A1: Tert-butyl 4-(6-benzyl-4-cyano-3-hydroxy-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate: Intermediate 5A (1.0 gm, 0.0018 mmol)** was dissolved in THF (20 ml ) and reaction mixture was stirred at RT, followed by addition of 10 % NaOH (5 ml) and stirred the mixture for 30 min. The reaction mixture was extracted with ethyl acetate. The combined THF and ethyl acetate layer was dried over sodium sulphate and concentrated under vacuum to get **Intermediate 6A1** as white solid (0.8 gm). 450.12  $[M+H]^+$ .

**Intermediates 6A2 Tert-butyl 4-(6-benzyl-4-cyano-3-hydroxy-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-(cyanomethyl)piperazine-1-carboxylate:**

**Intermediate 5B (1.0 gm, 0.0018 mmol)** was dissolved in THF (20 ml ) and reaction mixture was stirred at RT, followed by addition of 10 % NaOH (5 ml) and stirred the mixture for 30 min. The reaction mixture was extracted with ethyl acetate. The combined THF and ethyl acetate layer was dried over sodium sulphate and concentrated under vacuum to get

**Intermediate 6A2** as brown solid (0.8 gm). <sup>1</sup>H-NMR (400 MHz) (CDCl<sub>3</sub>): 7.30-7.22 (m, 5H), 4.41 (bs, 1H), 4.13-4.11 (m, 1H), 3.75 (bs, 1H), 3.62 (bs, 2H), 3.51-3.47 (m, 2H), 3.33-3.22 (m, 3H), 2.68 (bs, 2H), 2.44-2.39 (m, 5H), 1.43 (s, 9H). MS: m/z; 489.2 (M + 1).

**Intermediates 6B: tert-butyl 4-(6-benzyl-4-cyano-3-morpholino-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate:** K<sub>2</sub>CO<sub>3</sub> (0.29 gm, 0.0021 mol) was added to a to

solution of morpholine (0.112 ml, 0.0012 mol) in N-methyl Pyrrolidone (NMP, 4 ml) and stirred at RT. **Intermediate 5A** (0.5 gm, 0.00086 mol) in NMP was added to the reaction mixture dropwise followed by heating at 60 °C for 2 hr. Reaction mixture was quenched with water and extracted with ethyl acetate. Organic layer was washed with brine, dried over sodium sulphate and concentrated under vacuum to get crude residue which was purified by column chromatography using ethyl acetate: hexane (25 %) to get **Intermediate 6B** (0.4 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 7.38-7.34 (m, 4H), 7.30-7.7.29 (m, 1H), 3.81-3.79 (m, 4H), 3.76 (s, 2H), 3.70 (s, 2H), 3.61-3.58 (m, 4H), 3.51-3.47 (m, 4H), 3.28-3.26 (m, 4H), 2.58 (bs, 4H), 1.47 (s, 9H). 519.22 [M+H]<sup>+</sup>.

**Intermediates 6C: tert-butyl 4-(6-benzyl-4-cyano-3-(1,1-dioxidethiomorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate:**

Was prepared using the process as described above for **Intermediate 6B** using Thiomorpholine 1,1 dioxide (0.52 gm, 0.0051 mmol) and **Intermediate 5B** (1.5 gm, 0.0025 mol) to get

**Intermediates 6C** as white solid (1.25 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 7.38-7.32 (m, 4H), 7.31-7.30 (m, 1H), 4.12-4.10 (m, 4H), 3.76 (m, 4H), 3.52-3.50 (m, 4H), 3.28-3.25 (m, 4H), 3.18-3.16 (m, 4H), 2.78 (bs, 4H), 1.47 (s, 9H), 567.20 [M+H]<sup>+</sup>.

**Intermediates 7: 1-(4-aminopiperidin-1-yl)-6-benzyl-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:** To a solution of tert-butyl (1-(6-benzyl-3-chloro-4-cyano-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperidin-4-yl)carbamate (0.35 g) was dissolved in methanol (10 ml), triethylamine (20 ul) and Pd/C (0.35 g) and stirred reaction mixture for 12 hr at room temperature. After completion of the reaction, it was filtered over celite and mixture was evaporated to get oily compound (0.25 gm), we used next step directly without analytical data.

**Intermediate 7A: Tert-butyl 4-(6-benzyl-4-cyano-3-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-(cyanomethyl)piperazine-1-carboxylate.** Was prepared using the process as described above for **Intermediate 6C** using 2,6 dimorpholine (0.953 ml, 0.0051 mmol) and **Intermediate 5C** (3 gm, 0.0051 mmol) to get **Intermediates 7A** (2.6 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 7.38-7.34 (m, 4H), 7.30-7.28 (m, 1H), 4.68 (m, 2H), 4.13-4.07

(m, 3H), 3.84-3.76 (m, 4H), 3.67-3.61 (m, 4H), 3.13-3.08 (m, 2H), 2.77-2.6 (m, 3H), 2.65-2.64 (m, 3H), 2.48 (m, 2H), 1.48 (s, 9H), 1.29 (s, 3H), 1.20 (s, 3H), 586.29 [M+H]<sup>+</sup>.

**Intermediate 7B: tert-butyl 4-(6-benzyl-4-cyano-1-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)piperazine-1-carboxylate.** Was prepared using the process as described above for **Intermediate 6C** using tert-butyl piperazine-1-carboxylate (0.74 gm, 4.02 mmol) and **Intermediate E** (1.37 gm, 2.68 mmol) to get **Intermediate 7B** (1.2 gm). <sup>1</sup>H-NMR (400 MHz): δ 7.34 (m, 4H), 7.30 (m, 1H), 4.22-4.17 (q, 2H), 3.64 (s, 2H), 3.20 (t, 2H), 2.81-2.76 (m 1H), 2.60-2.58 (t, 2H), 2.40-2.31 (m, 2H), 1.26 (q, 3H). MS (m/z): 547.3 (M+1).

**Intermediate 7C: tert-butyl 4-(6-benzyl-4-cyano-1-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)-2-(cyanomethyl)piperazine-1-carboxylate.**

Was prepared using the process as described above for **Intermediate 7B** using 2-(piperazin-2-yl)acetonitrile dihydrochloride (1.6 gm, 13.1 mmol) and **Intermediate 5E** (4.4 gm, 8.6 mmol) to get **Intermediate 7C** (2.3 gm, 45.71%). MS (m/z): 547.3 (M+1).

**Intermediate 8: tert-butyl 4-(6-benzyl-4-cyano-3-(2-morpholinoethoxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate.**

To a solution of **Intermediate 5A** (1.6 gm, 0.0035 mmol) in DMSO (20 mL) was added NaH (60% in mineral oil) (213 mg, 0.0089 mmol) and stirred at 0 °C for 20 minutes. 4(2-chloroethyl morpholine. HCl) (1.3 gm, 0.0071 mmol) was added slowly and the reaction mixture was stirred at 80 °C for 3 hrs. The Reaction mixture was quenched with cold water (50 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic layer was washed with brine solution (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure to get crude product which was purified through column chromatography using ethyl acetate and *pet* ether (50 %) to get **Intermediate 8** as white solid (1 gm). <sup>1</sup>H-NMR (400 MHz): δ 7.37-7.34 (m, 4H), 7.32-7.30 (m, 1H), 4.49-4.46 (m, 4H), 3.77 (s, 2H), 3.73-3.69 (m, 6H), 3.51-3.50 (bs 4H), 3.29 (bs, 4H), 2.81-2.86 (m, 2H), 2.60 (bs, 8H), 1.47 (s, 9H). MS (m/z): 563.18(M+1)<sup>+</sup>.

**Intermediates 9A : tert-butyl 4-(6-benzyl-4-cyano-3-((methylsulfonyl)oxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate:** To a solution of **Intermediates 6A1** (2.1 gm, 0.0043 mol) in DCM (30 mL) was added TEA (1.5 mL, 0.0107 mol) at 0 °C. Then

methanesulphonyl chloride (0.5 mL, 0.0064 mol) solution in DCM (12 mL) was added slowly to the above solution and the reaction mixture was stirred at room temperature for 2 hrs. The reaction completion was checked by TLC using 40 % Ethyl acetate and hexane as mobile phase. The reaction mixture was quenched into cold water and organic layer was separated. The aqueous layer was extracted with more DCM (20 mL X 2) and the combined organic layer was washed with brine solution (20 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure and temp. (30-35 °C) to get a crude residue which was purified by column chromatography (100-200 mesh silica gel) using 20-40% Ethyl acetate in hexane as mobile phase. The pure fractions were collected and concentrated to get **Int 9A** (1.72 gm, 70.72%) as off-white solid, which used next reaction.

**Intermediates 9B : Tert-butyl 4-(6-benzyl-4-cyano-3-((methylsulfonyl)oxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-(cyanomethyl)piperazine-1-carboxylate:** Was prepared using the process as described above for Intemediates 9A. <sup>1</sup>H-NMR (400 MHz) (CDCl<sub>3</sub>): 7.36-7.26 (m, 5H), 4.62 (bs, 1H), 4.13-4.09 (m, 1H), 3.90-3.81 (m, 2H), 3.78-3.67 (m, 4H), 3.44 (s, 3H), 2.29-3.25 (m, 2H), 3.05-2.98 (m, 1H), 2.79-2.68 (m, 5H), 2.61-2.58 (m, 1H) 1.50 (s, 9H). MS: m/z; 567.2 (M + 1).

**Intermediate 10A: (tert-butyl 4-(6-benzyl-4-cyano-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate):** In a 100 mL pressure vessel, The suspension of **Intermediate 7A** (2.5 gm, 4.3 mmol), 1-methylpyrrolidine (0.99 gm, 8.6 mmol), Cs<sub>2</sub>CO<sub>3</sub> (4.2 gm, 12.9 mmol) and *rac* BINAP (0.53 gm, 0.86 mmol) in Toluene (38 mL) was purged with N<sub>2</sub> gas for 20 minutes. The Pd(OAc)<sub>2</sub> (0.096 gm, 0.43 mmol) was added to the above reaction mixture and stirred at 120 °C for 3 hrs. The Reaction mixture was quenched with cold water (40 mL) and extracted with ethyl acetate (20 mL x 2). The combined organic layer was washed with brine solution (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure to get crude product which was purified through column chromatography using ethyl acetate and *pet* ether (30-100%) to get **Intermediate 10A** (1.2 gm, 50.93%). <sup>1</sup>H-NMR (400 MHz): δ 7.38-7.26 (m, 5H), 4.32-4.23 (m, 2H), 3.78 (bs, 2H), 3.70 (bs, 2H), 3.52-3.43 (m, 4H), 3.31-3.28 (m, 4H), 3.11-3.07 (m, 1H), 2.70-2.66 (m, 1H), 2.60 (bs, 4H), 2.50 (s, 3H), 2.31-2.29 (m, 1H), 2.06-2.01 (m, 1H), 1.81-1.77 (m, 3H), 1.48 (s, 9H). MS (m/z): 547.3 (M+1), HPLC purity: 83.95%.

**Intermediates 10B: tert-butyl 4-(6-benzyl-4-cyano-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-(cyanomethyl)piperazine-1-carboxylate:**

**Method A :** Was prepared using the process as described above for **Intermediates 10A** <sup>1</sup>H-NMR (400 MHz) (CDCl<sub>3</sub>): 7.37-7.29 (m, 5H), 4.62 (bs, 2H), 4.33-4.21 (m, 1H), 3.90-3.62 (m, 8H), 3.48-3.39 (m, 2H), 3.20-3.12 (m, 2H), 2.92-2.51 (m, 9H), 2.37-2.24 (m, 2H), 2.20-2.05 (m, 1H), 2.00-1.89 (m, 2H) 1.50 (s, 9H). MS: m/z; 586.3 (M + 1).

**Method B:** In 500 mL sealed tube, (S)-(1-methylpyrrolidin-2-yl)methanol (6.2 gm, 0.054 mol) was added followed by addition of Dry THF (150 ml) stirred the reaction mixture 0°C. NaH (60%) (1.74 gm , 0.072 mol) was added in reaction mixture and stirred the reaction same temperature over 30 min under the nitrogen. **Intermediate 5** (18.5 g, 0.036 mol) was dissolved in dry THF (120 mL) added to the reaction mixture over dropwise and stirred at 85 °C for 12 hrs. After completion of reaction the RM was poured into saturated solution ammonium chloride (200 mL) and extracted with ethyl acetate (500mL X 2). The organic layer was dried over sodium sulphate and concentrated under reduced pressure to get a crude residue. The crude was purified by column chromatography using 3% DCM: Methanol as mobile phase. The pure fractions were collected and concentrated under reduced pressure to affords **Intermediate 6** (14 g) as light-yellow solid. <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 7.37-7.32 (m, 4H), 7.31-7.29 (m, 1H), 4.31 (bs, 1H), 3.90 (bs, 1H), 3.67 (bs, 1H), 3.65-3.55 (m, 1H), 3.48-3.44 (m, 1H), 3.18-3.14 (m, 2H), 2.85-2.82 (m, 6H). 2.63 (s, 3H), 2.45(m, 1H), 2.03-1.99 (m ,1H), 1.78.1.75 (m,6H), 1.50 (s, 9H), MS (m/z): 586.34 [M+H]<sup>+</sup>.

**Intermediate 11: tert-butyl4-(4-cyano-3-morpholino-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate**

In the 100 ml two neck RBF **Intermediate 6B** (0.9 gm, 1.59 mmol) in ethanol (18 mL) was purged with N<sub>2</sub> gas for 20 minutes, followed by addition of Pd(OH)<sub>2</sub>/C (20%, 0.27 gm, 0.3/w). The reaction mixture was stirred at 50 °C for 3 hrs under the H<sub>2</sub> atmosphere. The reaction completion was checked by TLC using MeOH: DCM (5 %). After completion of reaction, the mixture was filtered through celite bed under inert atmosphere and the filtrate was evaporated under reduced pressure to get a crude residue which was purified by column chromatography using 5% MeOH

in DCM as mobile phase. The pure fractions were collected and concentrated to get the desired product (0.4 gm, 52.78%). <sup>1</sup>H-NMR (400 MHz): δ 4.15-4.13 (m, 4H), 3.55-3.53 (m, 4H), 3.29-3.26 (m, 4H), 3.19-3.17 (m, 4H), 3.14-3.10 (m, 2H), 3.09-3.06 (m, 2H), 2.64-2.62 (m, 2H), 2.07 (s, 1H), 1.49 (s, 9H). MS (m/z): 477.2 (M+1).

**Intermediate 12: Tert-butyl 4-(4-cyano-3-(1,1-dioxidothiomorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate**

Was prepared using the process as described above for **Intermediate 11** using **Intermediate 6C** (0.9 gm, 0.0015 mmol) to get **Intermediate 12** as white solid (0.6 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 4.15-4.12 (m, 5H), 3.55-3.53 (m, 4H), 3.29-3.26 (m, 4H), 3.19-3.14 (m, 4H), 3.11-3.09 (m, 2H), 3.07-3.05 (m, 2H), 2.64-2.61 (m, 1H), 1.48 (s, 9H). 478.02 [M+H]<sup>+</sup>.

**Intermediate 13: tert-butyl 4-(4-cyano-3-(2-morpholinoethoxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate** : Was prepared using the process as described above for **Intermediate 11** using **Intermediate 8** (1.0 gm, 0.0017 mmol) to get **Intermediate 13** (0.3 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 4.49-4.46 (t, 2H), 4.11 (s, 4H), 3.73-3.71 (t, 4H), 3.54-3.52 (t, 4H), 3.30-3.81 (m, 4H), 3.01-2.99 (m, 2H), 2.91-2.78 (m, 2H), 2.61-2.59 (m, 4H), 2.50 (bs, 2H), 1.48 (s, 9H). 473.56 [M+H]<sup>+</sup>.

**Intermediate 14: tert-butyl 4-(4-cyano-3-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-(cyanomethyl)piperazine-1-carboxylate**

Was prepared using the process as described above for **Intermediate 11** using **Intermediate 7A** (2.6 gm, 0.0044 mmol) to get **Intermediate 14** as white solid (2.2 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 4.15-4.11 (m, 4H), 3.98 (s, 4H), 3.75-3.72 (m, 2H), 3.54-3.51 (m, 4H), 3.26-3.24 (m, 4H), 3.02-3.01 (m, 2H), 2.68-2.51 (m, 2H), 1.48 (s, 9H), 1.29 (s, 3H), 1.20 (s, 3H), 457.12 [M+H]<sup>+</sup>.

**Intermediate 15: (tert-butyl 4-(4-cyano-1-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)piperazine-1-carboxylate):**

Was prepared using the process as described above for **Intermediate 11** using **Intermediate 7A** (1.2 gm, 2.19 mmol) to get **Intermediate 15** (0.4 gm, 40%). <sup>1</sup>H-NMR (400 MHz): δ 4.15 (s, 2H),

3.76-3.72 (m, 8H), 3.60-3.56 (m, 4H), 2.09-3.06 (m, 2H), 2.66-2.60 (m, 4H), 2.04 (s, 1H), 1.48 (s, 9H), 1.24 (s, 3H), 1.22 (s, 3H). MS (m/z): 457.3 (M+1).

**Intermediate 16: (tert-butyl 4-(4-cyano-1-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)-2-(cyanomethyl)piperazine-1-carboxylate):**

Was prepared using the process as described above for **Intermediate 11** using **Intermediate 7B** (2.3 gm, 3.91 mmol) to get **Intermediate 16** (0.9 gm, 46.46%). MS: m/z; 496.3 (M + 1).

**Intermediate 17: (tert-butyl 4-(4-cyano-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate):**

Was prepared using the process as described above for **Intermediate 11** using **Intermediate 10A** (1.2 gm, 2.19 mmol) to get **Intermediate 17** (0.32 gm, 32.37%). MS (m/z): 457.2 (M+1).

**Intermediates 18: tert-butyl 4-(4-cyano-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-(cyanomethyl)piperazine-1-carboxylate:** In two neck 500 mL RBF, **Intermediates 10B** (10 gm, 0.017 mol) in Ethanol (200 mL) was degassed with N<sub>2</sub> for 20 minutes. Then methanolic ammonia solution (12 mL) was added to the above solution, followed by addition of 6 gm Pd(OH)<sub>2</sub>/C (20%). The entire RM was stirred at 70 °C under the atmosphere of H<sub>2</sub> gas for 24 hrs. The reaction completion was checked by TLC using 5% MeOH in DCM and 1 drop of methanolic ammonia. After completion of reaction, the mixture was filtered through celite bed under inert atmosphere and the filtrate was evaporated under reduced pressure to get the **Intermediates 17** desired product of light-yellow solid (7.3 gm). <sup>1</sup>H-NMR (400 MHz) (CDCl<sub>3</sub>): 4.81-4.78 (m, 1H), 4.61 (bs, 1H), 4.49-4.44 (m, 1H), 4.14-4.04 (m, 3H), 3.85-3.79 (m, 1H), 3.67-3.64 (m, 1H), 3.56-3.54 (m, 1H), 3.36-3.18 (m, 5H), 2.96-2.92 (m, 6H), 2.71-2.61 (m, 2H), 2.32-1.97 (m, 5H), 1.51 (s, 9H). MS (m/z): 496.3 (M+1).

**Intermediate 19A: tert-butyl 4-(6-(8-chloronaphthalen-1-yl)-4-cyano-3-morpholino-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate**

To a solution of **Intermediate 11** (0.4 g, 0.00075 mmol) in 1,4-dioxane (10 ml) purged under nitrogen gas for 20 min, was added 1-Bromo-8-bromo naphthalene (0.3 gm, 0.0015 mmol), Sodium tert.butoxide (0.29 gm, 0.0030 mmol) and r-BINAP (0.093 gm, 0.00015 mmol) over a

period of 10 min and stirred under Nitrogen atmosphere. Pd2(dba)3 (0.068 gm, 0.000075 mmol) was then added to the reaction mixture and heated at 130 °C for 16 hr. Reaction mixture was filtered over celite pad and filtrate, evaporated under reduced vacuum to get crude residue which was purified by column chromatography using MeOH: DCM (5%) to get **Intermediate 19 A** 1H-NMR ( $\delta$  ppm, CDCl<sub>3</sub>, 400 MHz): 7.77-7.75 (m, 1H), 7.64-7.62 (m, 1H), 7.53-7.51 (m, 1H), 7.46-7.42 (m, 1H), 7.31-7.32 (m, 1H), 7.23-7.21 (m, 1H), 4.58-4.53 (m, 1H), 3.87-3.81 (m, 1H), 3.64-3.62 (m, 4H), 3.59-3.54 (m, 4H), 3.52-3.49 (m, 2H), 3.23-3.22 (m, 2H), 3.15-3.05 (m, 2H), 2.60 (bs, 2H) 1.49 (s, 9H).

**Intermediate 19B: Tert-butyl 4-(4-cyano-3-(1,1-dioxidothiomorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate):**

Was prepared using the process as described above for Intermediate 19A using **Intermediate 12** get Intermediate **19B** as white solid (0.22 gm, 43.45%). 1H-NMR (400 MHz):  $\delta$  8.20-8.18 (m, 1H), 7.89-7.87 (m, 1H), 7.64 (d,  $J$  = 8.0 Hz, 1H), 7.53-7.50 (m, 2H), 7.46-7.43 (m, 1H), 7.19 (d,  $J$  = 6.8 Hz, 1H), 4.40 (bs, 2H), 4.18-4.15 (m, 4H), 3.60-3.58 (m, 4H), 3.36 (bs, 6H), 3.22-3.19 (m, 4H), 2.88 (bs, 2H), 1.50 (s, 9H). MS (m/z): 603.2 (M+1).

**Intermediate 19C : Tert-butyl 4-(4-cyano-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-(cyanomethyl)piperazine-1-carboxylate.**

Was prepared using the process as described above for Intermediate 19A using **Intermediate 14** (1 g, 0.0020 mmol), 1-Bromonaphthene (0.59 ml, 0.004 mmol), cesium carbonate (1.97 gm, 0.0066 mmol), Ruphos (0.18 gm, 0.0004 mmol) and Pd2(dba)3 (0.184 gm, 0.000022 mmol) with toluene as a solvent at 110 °C for 3 hr get **Intermediate 19C** as white solid (0.9 gm). 1H-NMR ( $\delta$  ppm, CDCl<sub>3</sub>, 400 MHz): 8.19-8.17 (m, 1H), 7.88-7.85 (m, 1H), 7.64-7.61 (m, 1H), 7.51-7.49 (m, 2H), 7.44-7.7.42 (m, 1H), 7.19-7.17 (m, 1H), 4.41 (bs, 1H), 4.40 (bs, 1H), 4.17-4.11 (m, 3H), 3.80-3.73 (m, 4H), 3.70 (bs, 1H), 2.25 (bs, 3H), 2.89-2.79 (m, 5H), 2.75-2.69 (m, 3H), 1.52 (s, 9H), 1.29 (s, 6H), 622.22[M+H]<sup>+</sup>.

**Intermediate 19 D: tert-butyl 4-(4-cyano-3-(2-morpholinoethoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate:** Was prepared using the process as described above for **Intermediate 19 A** using **Intermediate 13** (0.3 gm, 0.00063 mmol), 1-bromonaphthalene (0.18 mL, 0.001271mmol), Ruphos (0.06 gm, 0.00012 mmol), Cs<sub>2</sub>CO<sub>3</sub>

(0.13 gm, 0.00031mmol) and Pd<sub>2</sub>(dba)<sub>3</sub> (0.058 gm, 0.000063 mmol) with toluene as a solvent and at 110 °C for 4 hrs to get **Intermediate 19D** as white solid (0.25 gm, 18.17%). <sup>1</sup>H-NMR (400 MHz): δ 8.20-8.17 (m, 1H), 7.88-7.86 (m, 1H), 7.64-7.62 (m, 1 H), 7.52-7.50 (m, 2H), 7.48-7.43 (m, 1H), 7.18-7.17 (m, 1H), 4.54 (bs, 2H), 4.41(bs, 2H), 3.75 (bs, 4H), 3.58-3.57 (bs, 4H), 3.38 (bs, 5H), 2.85 (bs, 4H), 2.64 (bs, 4H), 1.49 (s, 9H), 599.21 (M+1)

**Intermediate 19E: tert-butyl 4-(6-(8-chloronaphthalen-1-yl)-4-cyano-3-(2-morpholinoethoxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate:**

Was prepared using the process as described above for **Intermediate 19A** using **Intermediate 13** (0.3 gm, 0.00063 mmol), 1-bromo-8-chloro naphthalene (0.36 mg, 0.001271mmol), Ruphos (0.06 gm, 0.00012 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.13 gm, 0.00031mmol) and Pd<sub>2</sub>(dba)<sub>3</sub> (0.058 gm, 0.000063 mmol) with toluene as a solvent and at 110 °C for 4 hrs to get Intermediate 19E as white solid (0.25 gm, 18.17%). <sup>1</sup>H-NMR (400 MHz): δ 7.78-7.75 (m, 1H), 7.65-7.63 (m, 1H), 7.54-7.52 (m, 1 H), 7.47-7.23 (m, 1H), 7.36-7.32(m, 1H), 7.24-7.23 (m, 1H), 4.60-4.48 (m, 3H), 3.94-3.74 (m, 1H), 3.64-3.61 (m, 4H), 3.54-3.52 (m, 2H), 3.49-3.44 (m, 5H), 3.28-3.26 (m, 2H), 3.24-3.12 (m, 2H), 2.80-2.52 (m, 4H), 1.49 (s, 9H), 634.20 (M+1)

**Intermediate 19 E : (tert-butyl 4-(4-cyano-1-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)piperazine-1-carboxylate)):**

Was prepared using the process as described above for Intermediate 19A using **Intermediate 16** (0.4 gm, 0.88 mmol), 1-bromonaphthalene (0.25 mL, 1.75 mmol), xantphos (0.1 gm, 0.17 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.86 gm, 2.63 mmol) and Pd<sub>2</sub>(dba)<sub>3</sub> with toluene as a solvent and at 110 °C for 4 hrs to get **Intermediate 19E** (0.32 gm, 63.7%). <sup>1</sup>H-NMR (400 MHz): δ 8.22-8.20 (m, 1H), 7.88-7.86 (m, 1H), 7.64-7.62 (m, 1 H), 7.52-7.50 (m, 2H), 7.46-7.42 (m, 1H), 7.20-7.18 (m, 1H), 4.38 (bs, 2H), 3.79-3.78 (m, 2H), 3.69-3.68 (m, 2H), 3.59-3.58 (m, 8H), 3.38-25 (m, 2H), 2.88-2.79 (m, 2H), 2.72-2.62 (m, 2H), 1.42 (s, 9H), 1.28 (s, 3H), 1.26 (s, 3H). MS (m/z): 583.3 (M+1).

**Intermediate 19G: (tert-butyl 4-(4-cyano-1-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl)-2-(cyanomethyl)piperazine-1-carboxylate):**

Was prepared using the process as described above for Intermediate 19A using **Intermediate 16** (0.88 gm, 1.78 mmol), 1-bromonaphthalene (0.53 mL, 3.56 mmol), xantphos (0.2 gm, 0.36 mmol),

Cs<sub>2</sub>CO<sub>3</sub> (1.72 gm, 5.34 mmol) and Pd<sub>2</sub>(dba)<sub>3</sub> (0.16 gm, 0.18 mmol) with toluene as a solvent and at 110 °C for 4 hrs to get **Intermediate 19F** as white solid (0.2 gm, 18.17%). MS (m/z): 622.3(M+1)

**Intermediate 19H: (tert-butyl 4-(4-cyano-3-((1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperazine-1-carboxylate):**

Was prepared using the process as described above for **Intermediate 19A** using **Intermediate 17** (0.32 gm, 0.71 mmol), 1-bromonaphthalene (0.21 mL, 1.42 mmol), RuPhos (0.066 gm, 0.14 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.7 gm, 2.13 mmol) and Pd<sub>2</sub>(dba)<sub>3</sub> (0.064 gm, 0.071 mmol) with toluene as a solvent and at 110 °C for 3 hrs to get **Intermediate 19G** (0.2 gm, 48.31%). <sup>1</sup>H-NMR (400 MHz): δ 8.20-8.18 (m, 1H), 7.88-7.85 (m, 1H), 7.64-7.62 (m, 1H), 7.53-7.48 (m, 2H), 7.46-7.41 (m, 1H), 7.19-7.17 (m, 1H), 4.40-3.70 (m, 4H), 3.67 (bs, 4H), 3.30-3.12 (m, 5H), 3.11-2.87 (m, 1H), 2.75 (bs, 2H), 2.73-2.54 (m, 1H), 2.53 (s, 3H), 2.31-2.08 (m, 1H), 2.07-2.01 (m, 1H), 1.87-1.68 (m, 4H), 1.42 (s, 9H). MS (m/z): 583.3 (M+1).

**Intermediates 19I: tert-butyl 4-(6-(8-chloronaphthalen-1-yl)-4-cyano-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-(cyanomethyl)piperazine-1-carboxylate:**

In 500 mL sealed tube, **Intermediate 18** (7 gm, 0.014 mol), 1-bromo-8-chloronaphthalene (5.01 gm, 0.027 mol), Xantphos (1.6 gm, 0.002 mol) and Cs<sub>2</sub>CO<sub>3</sub> (13.8 gm, 0.042 mol) in Toluene (140 mL) was degassed with N<sub>2</sub> for 20 minutes. Then Pd<sub>2</sub>(dba)<sub>3</sub> (1.3 gm, 0.0014 mol) was added to the above solution and entire RM was stirred at 120 °C for 12 hrs. The reaction completion was checked by TLC using 5% MeOH in DCM and 1 drop of methanolic ammonia. After completion of reaction, the mixture was poured in cold water (20 mL) and extracted with ethyl acetate (30 mL X 2). The organic layer was washed with brine solution (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure to get a crude residue which was purified by column chromatography (100-200 mesh silica gel) using 3% MeOH in DCM as mobile phase. The pure fractions were collected and concentrated to get **Intermediates 19I as the** desired product (7.26 gm). <sup>1</sup>H-NMR (400 MHz) (CDCl<sub>3</sub>): 7.77-7.75 (m, 1H), 7.66-7.62 (m, 1H), 7.53-7.51 (m, 1H), 7.48-7.42 (m, 1H), 7.40-7.32 (m, 1H), 7.28-7.18 (m, 1H), 4.59-4.55 (m, 2H), 4.34-4.30 (m, 2H), 3.90-3.77 (m, 1H), 3.60-3.55 (m, 2H), 3.34-3.31 (m, 1H), 3.19-3.13 (m, 1H), 3.09-3.03 (m, 4H),

2.73-2.64 (m, 3H), 2.53(s, 3H), 2.33-2.31 (m, 1H), 2.06-2.03(m, 1H), 1.85-1.78 (m, 5H), 1.51 (s, 9H). MS (m/z): 656.3 (M+1). HPLC: 99.01%.




**Intermediates 19J: tert-butyl 4-(6-(3-(benzyloxy)naphthalen-1-yl)-4-cyano-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)-2-**













**(cyanomethyl)piperazine-1-carboxylate:** Was prepared using the process as described above for **Intermediate 19A** using Intermediates 18 (1.4 gm, 0.0028 mol), 3-(benzyloxy)-1-bromonaphthalene (1.77 gm, 0.0056 mol), Xantphos (0.32 gm, 0.00056 mol), Cs<sub>2</sub>CO<sub>3</sub> (2.7 gm, 0.0084 mol), Toluene (20 mL) and Pd<sub>2</sub>(dba)<sub>3</sub> (0.26 gm, 0.00028 mol) to get the desired product of Intermediates **19J** (1 gm, 49.06%). MS (m/z): 728.5 (M+1). HPLC: 80.75%.













**General procedure for Deboc (Method 20)**










In 250 ml Single neck RBF , a solution of Intermediate 19A to 19I (1.9 gm, 0.0022 mol) in DCM (19 mL) was added TFA (10 ml) at 0 °C for 1 hr. The reaction completion was checked by TLC using Methanol: DCM (5%) and 1 drop of methanolic ammonia. The solvent was evaporated under reduced pressure to get crude solid of deprotected boc, we have used next step without analytical data.

**Intermediates IUPAC**

|                                                                                     |                                                                                      |                                                                                       |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| <b>Int 1</b>                                                                        | <b>Int 2</b>                                                                         | <b>Int 3</b>                                                                          |
|  |  |  |
| <b>Int 4A</b>                                                                       | <b>Int 5</b>                                                                         | <b>Int 5A</b>                                                                         |

|                                                                                     |                                                                                     |                                                                                       |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
|    |   |    |
| <b>Int 5B</b>                                                                       | <b>Int 5C</b>                                                                       | <b>Int 5D</b>                                                                         |
|    |    |    |
| <b>Int 5E</b>                                                                       | <b>Int 6</b>                                                                        | <b>Int 6A1</b>                                                                        |
|  |  |  |
| <b>Int 6A2</b>                                                                      | <b>Int 6B</b>                                                                       | <b>Int 6C</b>                                                                         |
|  |  |  |

|                                                                                     |                                                                                      |                                                                                       |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| <b>Int 7</b>                                                                        | <b>Int 7A</b>                                                                        | <b>Int 7B</b>                                                                         |
|    |    |    |
| <b>Int 7C</b>                                                                       | <b>Int 8</b>                                                                         | <b>Int 9A</b>                                                                         |
|   |    |    |
| <b>Int 9B</b>                                                                       | <b>Int 10A</b>                                                                       | <b>Int 10B</b>                                                                        |
|  |  |  |
| <b>Int 11</b>                                                                       | <b>Int 12</b>                                                                        | <b>Int 14</b>                                                                         |
|  |   |  |

|                                                                                     |                                                                                      |                                                                                       |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| <b>Int 14</b>                                                                       | <b>Int 15</b>                                                                        | <b>Int 16</b>                                                                         |
|    |    |    |
| <b>Int 17</b>                                                                       | <b>Int 18</b>                                                                        | <b>Int 19A</b>                                                                        |
|    |    |   |
| <b>Int 19B</b>                                                                      | <b>Int 19 C</b>                                                                      | <b>Int 19D</b>                                                                        |
|  |  |  |
| <b>Int 19E</b>                                                                      | <b>Int 19F</b>                                                                       | <b>Int 19G</b>                                                                        |

|                |                |                |
|----------------|----------------|----------------|
|                |                |                |
| <b>Int 19H</b> | <b>Int 19I</b> | <b>Int 19J</b> |
|                |                |                |

### Part-B - Preparation of Compounds

**Example 1 : 1-(4-acryloylpiperazin-1-yl)-3-(1,1-dioxidothiomorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:** In single Neck 100 mL RBF. **Method 20** (0.2 gm, 0.39 mmol) in DCM (5 mL) was added DIEPA (0.21 mL, 1.17 mmol) at 0 °C and stirred for 10 minutes. The acryloyl chloride (0.06 mL, 0.79 mmol) in DCM (3 mL) was added slowly to the above solution at 0 °C. The reaction mixture was stirred at 0 °C for 40 minutes. The reaction completion was checked by TLC using MeOH: DCM (5%). The reaction mixture was quenched with saturated solution of NaHCO<sub>3</sub> (10 mL) and stirred the entire solution for 10 minutes then isolated the organic layer. The aqueous layer again extracted with DCM (10 mL X 2) and the combined organic layers were washed with brine solution (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to get a crude residue which was purified by column chromatography using 2-3% MeOH in DCM as mobile phase. The pure fractions were collected and concentrated to get desired product (0.065 gm, 29.94%). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): δ 7.25 (m, 5H), 6.59 (dd, 1H), 6.34 (dd, 1H), 5.75 (dd, 1H), 4.39 (s, 2H), 3.82 (s, 3H), 3.74 (m, 7H), 3.24 (m, 4H), 3.08 (t, 2H), 2.54 (t, 4H), 2.35 (d, 3H), 1.25 (s, 1H), 1.19 (s, 1H). MS (m/z): 557.2 [M+H]<sup>+</sup>. HPLC purity : 95.88%.

**Example 2 : 1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-morpholino-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile :** Was prepared using the process as described above for **Example1** to get 0.06 gm of 1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-morpholino-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile. <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): δ 7.36-7.33 (m, 4H), 7.31-7.28 (m, 1H), 6.62-6.55 (m, 1H), 6.35-6.31 (m, 1H), 5.76-5.73 (m, 1H), 4.33-4.23 (m, 2H), 3.79-3.77 (bs, 4H), 3.70-3.66 (bs, 4H), 3.36 (bs, 4H), 3.12-3.08 (m, 1H), 2.72-2.68 (m, 1H), 2.61-2.59 (bs, 4H), 2.51 (bs, 3H), 2.34-2.30 (m, 1H), 2.06-2.01 (m, 1H), 1.83-1.67 (m, 3H). MS (m/z): 543.2 [M+H]<sup>+</sup>. HPLC purity: 96.69%.

**Example 3: 1-(4-acryloylpiperazin-1-yl)-3-(2-morpholinoethoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:** Was prepared using the process as described above for **Example1** to get 0.17 gm of 1-(4-acryloylpiperazin-1-yl)-3-(2-morpholinoethoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile. <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): δ 7.36-7.33 (m, 4H), 7.31-7.28 (m, 1H), 6.62-6.55 (m, 1H), 6.35-6.31 (m, 1H), 5.76-5.73 (m, 1H), 4.33-4.23 (m, 2H), 3.79-3.77 (bs, 4H), 3.70-3.66 (bs, 4H), 3.36 (bs, 4H), 3.12-3.08 (m, 1H), 2.72-2.68 (m, 1H), 2.61-2.59 (bs, 4H), 2.51 (bs, 3H), 2.34-2.30 (m, 1H), 2.06-2.01 (m, 1H), 1.83-1.67 (m, 3H). MS (m/z): 553.3 [M+H]<sup>+</sup>. HPLC purity: 96.11%.

**Example 4: 1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(2-morpholinoethoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile :** Was prepared using the process as described above for **Example1** to get 0.1 gm of 1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(2-morpholinoethoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile. <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): δ 7.36-7.33 (m, 4H), 7.31-7.28 (m, 1H), 6.62-6.55 (m, 1H), 6.35-6.31 (m, 1H), 5.76-5.73 (m, 1H), 4.33-4.23 (m, 2H), 3.79-3.77 (bs, 4H), 3.70-3.66 (bs, 4H), 3.36 (bs, 4H), 3.12-3.08 (m, 1H), 2.72-2.68 (m, 1H), 2.61-2.59 (bs, 4H), 2.51 (bs, 3H), 2.34-2.30 (m, 1H), 2.06-2.01 (m, 1H), 1.83-1.67 (m, 3H). MS (m/z): 587.3 [M+H]<sup>+</sup>. HPLC purity: 96.11%.

**Example 5: 3-(4-acryloylpiperazin-1-yl)-1-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.:** Was prepared using the process as described above for **Example1** to get 0.12 gm of 3-(4-acryloylpiperazin-1-yl)-1-(2,6-

dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.  
 1H-NMR ( $\delta$  ppm, CDCl<sub>3</sub>, 400 MHz):  $\delta$  7.36-7.33 (m, 4H), 7.31-7.28 (m, 1H), 6.62-6.55 (m, 1H), 6.35-6.31 (m, 1H), 5.76-5.73 (m, 1H), 4.33-4.23 (m, 2H), 3.79-3.77 (bs, 4H), 3.70-3.66 (bs, 4H), 3.36 (bs, 4H), 3.12-3.08 (m, 1H), 2.72-2.68 (m, 1H), 2.61-2.59 (bs, 4H), 2.51 (bs, 3H), 2.34-2.30 (m, 1H), 2.06-2.01 (m, 1H), 1.83-1.67 (m, 3H). MS (m/z): 537.3 [M+H]<sup>+</sup>. HPLC purity: 98.23%.

**Example 6: 3-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-1-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:** Was prepared using the process as described above for **Example 1** to get 0.1 gm of 3-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-1-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile. 1H-NMR ( $\delta$  ppm, CDCl<sub>3</sub>, 400 MHz):  $\delta$  7.36-7.33 (m, 4H), 7.31-7.28 (m, 1H), 6.62-6.55 (m, 1H), 6.35-6.31 (m, 1H), 5.76-5.73 (m, 1H), 4.33-4.23 (m, 2H), 3.79-3.77 (bs, 4H), 3.70-3.66 (bs, 4H), 3.36 (bs, 4H), 3.12-3.08 (m, 1H), 2.72-2.68 (m, 1H), 2.61-2.59 (bs, 4H), 2.51 (bs, 3H), 2.34-2.30 (m, 1H), 2.06-2.01 (m, 1H), 1.83-1.67 (m, 3H). MS (m/z): 571.3 [M+H]<sup>+</sup>. HPLC purity: 98.08%.

**Example 7 : 3-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-1-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile. :** Was prepared using the process as described above for **Example 1** to get desired product (0.04 gm, 17.03%). 1H-NMR ( $\delta$  ppm, CDCl<sub>3</sub>, 400 MHz):  $\delta$  7.25 (m, 5H), 6.59 (dd, 1H), 6.34 (dd, 1H), 5.75 (dd, 1H), 4.39 (s, 2H), 3.82 (s, 3H), 3.74 (m, 7H), 3.24 (m, 4H), 3.08 (t, 2H), 2.54 (t, 4H), 2.35 (d, 3H), 1.25 (s, 1H), 1.19 (s, 1H). MS (m/z): 576.2 [M+H]<sup>+</sup>. HPLC purity: 95.4%.

**Example 8: (S)-1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.**

Was prepared using the process as described above for **Example 1** to afford (S)-1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.05 gm, 12%) as off white solid. 1H-NMR (400 MHz) (CDCl<sub>3</sub>): 7.77 (d,  $J$  = 6.8 Hz, 1H), 7.67-7.65 (m, 1H), 7.54-7.52 (m, 1H), 7.36-7.35 (m, 1H), 7.34-7.28 (m, 1H), 6.64-6.58 (m, 1H), 6.37-6.32 (m, 1H), 5.85-5.71 (m, 1H), 4.94-4.92 (m, 1H), 4.59-4.51 (m, 2H), 3.94-3.80 (m, 2H), 3.81-3.65 (m, 2H), 3.64-3.61 (m, 2H), 3.60-3.54

(m, 2H), 3.34-3.28 (m, 2H), 3.16-3.10 (m, 2H), 2.92 (s, 3H), 2.62-2.59 (m, 2H), 2.28-2.24 (m, 2H), 2.06-2.01 (m, 2H), 1.41-1.37 (m, 2H). MS (m/z): 571.2 (M+1). HPLC purity: 94.39%.

**Example 9: (S)-1-(4-acryloylpiperazin-1-yl)-6-(3-hydroxynaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:** Was prepared using the process as described above for **Example 1** to get the desired product of (S)-1-(4-acryloylpiperazin-1-yl)-6-(3-hydroxynaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.035 gm) as white solid. <sup>1</sup>H-NMR (400 MHz) (CDCl<sub>3</sub>): 7.98 (d, *J* = 6.4 Hz, 1H), 7.65 (d, *J* = 6.8 Hz, 1H), 7.42-7.40 (m, 1H), 7.32-7.29 (m, 1H), 6.90 (s, 1H), 6.74 (s, 1H), 6.59-6.53 (m, 1H), 6.35-6.32 (d, *J* = 14 Hz, 1H), 5.75 (d, *J* = 8.4 Hz, 1H), 4.48-4.44 (m, 1H), 4.33-4.30 (m, 2H), 4.21-4.18 (m, 1H), 3.78-3.61 (m, 4H), 3.36-3.33 (m, 5H), 3.18-3.15 (m, 1H), 2.83-2.79 (m, 2H), 2.62 (s, 3H), 2.10-2.06 (m, 2H), 1.82-1.81 (m, 1H), 1.78-1.74 (m, 2H), 1.44-1.41 (m, 2H). MS (m/z): 553.5 (M+1). HPLC purity: 94.12%.

**Example 10: (S)-1-(4-(2-fluoroacryloyl)piperazin-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-6-(quinazolin-4-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.:** To the 100 mL two neck RBF, a suspension of (S)-3-((1-methylpyrrolidin-2-yl)methoxy)-1-(piperazin-1-yl)-6-(quinazolin-4-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile hydrochloride (0.3 gm, 0.00062 mol) in ethyl acetate (1.8 mL) at 0 °C was added triethylamine (0.7 mL, 0.00496 mol), 2-fluoroprop-2-enoic acid (0.11 gm, 0.00124 mol) and T3P (1.2 mL, 0.00186 mol, 50 wt. % in ethyl acetate). The mixture was warmed to 15 °C for 30 min and the reaction mixture was diluted with satd aq sodium carbonate (10 mL). The aqueous phase was extracted with ethyl acetate (15 mL X 2) and the combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to provide the crude residue. The residue was purified by prep-HPLC; column: Waters Xbridge C18 150 x 50 mm x 10 μm, mobile phase: A [water (10 mM NH<sub>4</sub>HCO<sub>3</sub>)], B (ACN), B%: 42%–72%, 11.5 min); to afford (S)-1-(4-(2-fluoroacryloyl)piperazin-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-6-(quinazolin-4-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.065 gm, 18.83%). MS (m/z): 557.2 (M+1).

**Example 11: (S)-6-(8-chloronaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-1-(4-(vinylsulfonyl)piperazin-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.:** In Two neck 100 mL RBF, a suspension of (S)-6-(8-chloronaphthalen-1-yl)-3-((1-methylpyrrolidin-2-

yl)methoxy)-1-(piperazin-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile hydrochloride (0.32 gm, 0.00062 mol) in DCM (4 mL) was added TEA (0.26 mL, 0.00186 mol) at 0 °C. After 5 min, the solution of 2-chloroethanesulfonyl chloride (0.1 mL, 0.00124 mol) in DCM (8.8 mL) was added dropwise and stirred for at RT 12 hrs. The completion of reaction was checked by TLC using methanol: DCM (5%) and 1 drop of methanolic ammonia as mobile phase. The RM was concentrated under reduced pressure to get a crude mass which was purified by column chromatography (100-200 mesh silica gel) using 5-8% MeOH in DCM as mobile phase to afford (S)-6-(8-chloronaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-1-(4-(vinylsulfonyl)piperazin-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.04 gm, 10.6%) as white solid. <sup>1</sup>H-NMR (400 MHz) (CDCl<sub>3</sub>): 7.79-7.76 (m, 1H), 7.67-7.64 (m, 1H), 7.57-7.44 (m, 2H), 7.38-7.33 (m, 1H), 7.28-7.26 (m, 1H), 6.49-6.47 (m, 1H), 6.33-6.29 (m, 1H), 6.15-6.11 (m, 1H), 5.21 (bs, 1H), 4.58-4.54 (m, 2H), 3.96-3.90 (m, 2H), 3.67-3.55 (m, 4H), 3.47-3.42 (m, 2H), 3.39-3.34 (m, 2H), 3.30-3.26 (m, 2H), 3.16-2.86 (m, 6H), 2.59-2.50 (m, 1H), 2.36-2.32 (m, 2H), 2.13-2.07 (m, 2H). MS (m/z): 607.4 (M+1). HPLC purity: 92.22%.

**Example 12 : 6-(8-chloronaphthalen-1-yl)-1-(4-(2-fluoroacryloyl)-3-methylpiperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-**

**carbonitrile.:** Was prepared using the process as described above for **Example 10** to get crude product which was further purified by prep-HPLC; column: Sunfire C18 150 x 50 mm x 10 µm, mobile phase: A [water (10 mM NH<sub>4</sub>HCO<sub>3</sub>)], B (ACN), B%: 42%–72%; to afford 6-(8-chloronaphthalen-1-yl)-1-((R)-4-(2-fluoroacryloyl)-3-methylpiperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.16 gm, 22.4%). <sup>1</sup>H-NMR (400 MHz) (CDCl<sub>3</sub>): 7.79-7.76 (m, 1H), 7.67-7.64 (m, 1H), 7.55-7.52 (m, 1H), 7.50-7.42 (m, 1H), 7.37-7.33 (m, 1H), 7.28-7.21 (m, 1H), 5.35-5.14 (m, 2H), 4.80-4.69 (m, 2H), 4.62-4.51 (m, 3H), 3.99-3.89 (m, 2H), 3.75-3.55 (m, 4H), 3.51-3.40 (m, 2H), 3.34-2.53 (m, 8H), 2.29-1.99 (m, 4H), 1.50-1.19 (m, 3H). MS (m/z): 603.2 (M+1). HPLC purity: 96.3% (**considered with diastereomeric fractions**).

**Example 13: 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:** Was prepared using the process as described above for **Example 1** to get 0.85 gm of 1-(4-acryloyl-3-

(cyanomethyl)piperazin-1-yl)-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile. The racemic mixture (0.8 gm) was isolated by chiral separation using CHIRALCEL-ODH (4.6 X 250 mm) 5  $\mu$ m and mobile phase; acetonitrile (100%) to provide 0.33 gm & 0.36 gm of isomers 1 and isomer 2 respectively **as example 14 and example 15**. <sup>1</sup>H-NMR ( $\delta$  ppm, CDCl<sub>3</sub>, 400 MHz):  $\delta$  7.36-7.33 (m, 4H), 7.31-7.28 (m, 1H), 6.62-6.55 (m, 1H), 6.35-6.31 (m, 1H), 5.76-5.73 (m, 1H), 4.33-4.23 (m, 2H), 3.79-3.77 (bs, 4H), 3.70-3.66 (bs, 4H), 3.36 (bs, 4H), 3.12-3.08 (m, 1H), 2.72-2.68 (m, 1H), 2.61-2.59 (bs, 4H), 2.51 (bs, 3H), 2.34-2.30 (m, 1H), 2.06-2.01 (m, 1H), 1.83-1.67 (m, 3H). MS (m/z): 576.2 [M+H]<sup>+</sup>. HPLC purity: 96.72%.

**Example 14 : 1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile** : <sup>1</sup>H-NMR ( $\delta$  ppm, CDCl<sub>3</sub>, 400 MHz):  $\delta$  7.36-7.33 (m, 4H), 7.31-7.28 (m, 1H), 6.62-6.55 (m, 1H), 6.35-6.31 (m, 1H), 5.76-5.73 (m, 1H), 4.33-4.23 (m, 2H), 3.79-3.77 (bs, 4H), 3.70-3.66 (bs, 4H), 3.36 (bs, 4H), 3.12-3.08 (m, 1H), 2.72-2.68 (m, 1H), 2.61-2.59 (bs, 4H), 2.51 (bs, 3H), 2.34-2.30 (m, 1H), 2.06-2.01 (m, 1H), 1.83-1.67 (m, 3H). MS (m/z): 576.2 [M+H]<sup>+</sup>. HPLC purity: 97.62%.

**Example 15: 1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile** : <sup>1</sup>H-NMR ( $\delta$  ppm, CDCl<sub>3</sub>, 400 MHz):  $\delta$  7.36-7.33 (m, 4H), 7.31-7.28 (m, 1H), 6.62-6.55 (m, 1H), 6.35-6.31 (m, 1H), 5.76-5.73 (m, 1H), 4.33-4.23 (m, 2H), 3.79-3.77 (bs, 4H), 3.70-3.66 (bs, 4H), 3.36 (bs, 4H), 3.12-3.08 (m, 1H), 2.72-2.68 (m, 1H), 2.61-2.59 (bs, 4H), 2.51 (bs, 3H), 2.34-2.30 (m, 1H), 2.06-2.01 (m, 1H), 1.83-1.67 (m, 3H). MS (m/z): 576.2 [M+H]<sup>+</sup>. HPLC purity: 97.31%.

**Example 16: 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.** Was prepared using the process as described above for **Example 1 to get** The pure fractions were collected and concentrated to get the desired product (0.61 gm, 34.51%). <sup>1</sup>H-NMR (400 MHz) (CDCl<sub>3</sub>): 8.20-8.17 (m, 1H), 7.88-7.86 (m, 1H), 7.64 (d, *J* = 8.4 Hz, 1H), 7.53-7.51 (m, 2H), 7.50-7.44 (m, 1H), 7.18 (d, *J* = 7.2 Hz, 1H), 6.64-6.59 (m, 1H), 6.42-6.35 (m, 1H), 5.84-5.77 (m, 1H), 4.94-4.91 (m, 2H), 4.49-4.41 (m, 4H), 4.03-3.95 (m, 2H), 3.86-3.83 (m, 1H), 3.58-3.31 (m, 7H),

3.02-2.98 (m, 5H), 2.25-2.23 (m, 2H), 2.03-1.98 (m, 3H), 1.41-1.29 (m, 1H). MS (m/z): 576.25 (M+1). HPLC purity: 95.04%.

**Example 17: 1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile**

1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.13gm) was isolated by chiral separation using CHIRALCEL-ODH (4.6 X 250 mm) 5 µm and mobile phase; acetonitrile (100%) from the racemic mixture of 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.57 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): δ 8.19-8.17 (m, 1H), 7.88-7.86 (m, 1H), 7.64 (d, *J* = 6 Hz, 1H), 7.52-7.51 (m, 2H), 7.46-7.43 (m, 1H), 7.18 (d, *J* = 6 Hz, 1H), 6.61 (bs, 1H), 6.40 (d, *J* = 12.4 Hz, 1H), 5.83 (d, *J* = 8.4 Hz, 1H), 5.09 (bs, 1H), 4.86 (bs, 2H), 4.51-4.43 (m, 4H), 4.01-3.84 (m, 4H), 3.59-3.35 (m, 4H), 3.23-3.11 (m, 2H), 3.01-2.96 (m, 2H), 2.84 (s, 3H), 2.27-2.16 (m, 2H), 2.03-1.99 (m, 2H), 1.41-1.36 (m, 1H). MS (m/z): 576.5 [M+H]<sup>+</sup>. HPLC purity: 96.8%.

**Example 18: 1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.:**

1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.125 gm) was isolated by chiral separation using CHIRALCEL-ODH (4.6 X 250 mm) 5 µm and mobile phase; acetonitrile (100%) from racemic mixture of 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.57 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): δ 8.19-8.17 (m, 1H), 7.88-7.86 (m, 1H), 7.64 (d, *J* = 6 Hz, 1H), 7.52-7.50 (m, 2H), 7.44-7.43 (m, 1H), 7.18 (d, *J* = 6 Hz, 1H), 6.60 (bs, 1H), 6.40 (d, *J* = 13.2 Hz, 1H), 5.83 (d, *J* = 8.4 Hz, 1H), 5.11-5.05 (m, 1H), 4.84-4.80 (m, 1H), 4.53-4.39 (m, 4H), 3.98-3.95 (m, 1H), 3.84-3.82 (m, 1H), 3.63 (bs, 2H), 3.36-3.33 (m, 4H), 3.11-3.10 (m, 2H), 3.02-2.95 (m, 2H), 2.86 (s, 3H), 2.78-2.75 (m, 1H), 2.26-2.14 (m, 2H), 2.02-1.98 (m, 2H), 1.37-1.32 (m, 1H). MS (m/z): 576.5 [M+H]<sup>+</sup>. HPLC purity: 93.99%.

**Example 19: 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(3-hydroxynaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.:** Was prepared using the process as described above for **Example 1 to get** 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(3-hydroxynaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile, was further purified by prep-HPLC; column: Sunfire C18 150 x 50 mm x 10  $\mu$ m, mobile phase: A [water (10 mM  $\text{NH}_4\text{HCO}_3$ )], B (ACN), B%: 42%–72%) to afford 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(3-hydroxynaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.05 gm) as white solid.  $^1\text{H-NMR}$  (400 MHz) ( $\text{CDCl}_3$ ): 8.00-7.96 (m, 1H), 7.64 (m,  $J = 6$  Hz, 1H), 7.42-7.39 (m, 1H), 7.32-7.29 (m, 1H), 6.90 (s, 1H), 6.70 (s, 1H), 6.55 (bs, 1H), 6.37 (d,  $J = 13.2$  Hz, 1H), 5.81 (d,  $J = 8.4$  Hz, 1H), 5.01-4.92 (m, 1H), 4.59-4.58 (m, 1H), 4.34-4.26 (m, 3H), 3.85-3.82 (m, 1H), 3.76-3.64 (m, 2H), 3.44-3.24 (m, 4H), 2.95-2.79 (m, 5H), 2.71 (s, 3H), 2.49 (bs, 2H), 2.10-1.99 (m, 3H), 1.88-1.82 (m, 2H), 1.62-1.60 (m, 1H). MS ( $m/z$ ): 592.5 ( $M+1$ ). HPLC purity: 98.62%.

**Example 20: 1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile. :** Was prepared using the process as described above for **Example 1 to get** to provide the crude residue. The residue was purified by prep-HPLC; column: Sunfire C18 150 x 50 mm x 10  $\mu$ m, mobile phase: A [water (10 mM  $\text{NH}_4\text{HCO}_3$ )], B (ACN), B%: 42%–72%); to afford 1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.09 gm, 26.6%).  $^1\text{H-NMR}$  (400 MHz) ( $\text{CDCl}_3$ ): 8.19-8.17 (m, 1H), 7.88-7.85 (m, 1H), 7.64 (d,  $J = 8.0$  Hz, 1H), 7.54-7.49 (m, 2H), 7.46-7.42 (m, 1H), 7.18 (d,  $J = 7.6$  Hz, 1H), 5.48-5.36 (m, 1H), 5.28-5.23 (m, 1H), 4.92 (bs, 2H), 4.50-4.43 (m, 3H), 4.09-3.95 (m, 2H), 3.84-3.81 (m, 1H), 3.56-3.31 (m, 6H), 3.09-2.71 (m, 8H), 2.31-2.15 (m, 2H), 2.06-1.97 (m, 2H), 1.43-1.41 (m, 1H). MS ( $m/z$ ): 594.4 ( $M+1$ ). HPLC purity: 95.35%.

**Example 21: (S)-1-(4-acryloylpiperazin-1-yl)-6-(isoquinolin-4-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.:** Was prepared using the process as described above for **Example 1 to get** to get a crude residue. The residue was purified

by prep-HPLC; column: Sunfire C18 150 x 50 mm x 10  $\mu$ m, mobile phase: A [water (10 mM  $\text{NH}_4\text{HCO}_3$ )], B (ACN), B%: 42%–72%]; to afford (S)-1-(4-acryloylpiperazin-1-yl)-6-(isoquinolin-4-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.04 gm, 12%).  $^1\text{H-NMR}$  (400 MHz) ( $\text{CDCl}_3$ ): 9.05 (s, 1H), 8.28 (m, 1H), 8.13 (d,  $J = 6.4$  Hz, 1H), 8.01 (d,  $J = 6.4$  Hz, 1H), 7.76-7.73 (m, 1H), 7.66-7.63 (m, 1H), 6.64-6.58 (m, 1H), 6.35 (d,  $J = 14.0$  Hz, 1H), 5.77 (d,  $J = 8.8$  Hz, 1H), 4.47-4.33 (m, 4H), 3.84-3.73 (m, 4H), 3.49-3.44 (m, 6H), 3.19 (bs, 1H), 2.87-2.80 (m, 3H), 2.58 (s, 3H), 2.39-2.31 (m, 1H), 2.09-2.04 (m, 2H), 2.03-1.92 (m, 2H). MS ( $m/z$ ): 538.5 ( $M+1$ ). HPLC purity: 97.64%.

**Example 22: (S)-1-(4-acryloylpiperazin-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-6-(quinolin-8-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:** Was prepared using the process as described above for **Example 1** to get crude residue. The residue was purified by prep-HPLC; column: Sunfire C18 150 x 50 mm x 10  $\mu$ m, mobile phase: A [water (10 mM  $\text{NH}_4\text{HCO}_3$ )], B (ACN), B%: 42%–72%]; to afford (S)-1-(4-acryloylpiperazin-1-yl)-6-(isoquinolin-4-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.04 gm, 12%).  $^1\text{H-NMR}$  (400 MHz) ( $\text{CDCl}_3$ ): 9.05 (s, 1H), 8.28 (m, 1H), 8.13 (d,  $J = 6.4$  Hz, 1H), 8.01 (d,  $J = 6.4$  Hz, 1H), 7.76-7.73 (m, 1H), 7.66-7.63 (m, 1H), 6.64-6.58 (m, 1H), 6.35 (d,  $J = 14.0$  Hz, 1H), 5.77 (d,  $J = 8.8$  Hz, 1H), 4.47-4.33 (m, 4H), 3.84-3.73 (m, 4H), 3.49-3.44 (m, 6H), 3.19 (bs, 1H), 2.87-2.80 (m, 3H), 2.58 (s, 3H), 2.39-2.31 (m, 1H), 2.09-2.04 (m, 2H), 2.03-1.92 (m, 2H). MS ( $m/z$ ): 538.5 ( $M+1$ ). HPLC purity: 97.64%.

**Example 23: 1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:** To **Intermediate 9** (8 gm, 0.014 mol) in DCM (80 ml) was added DIPEA (5.1 ml, 0.028 mol) at 0  $^\circ\text{C}$ . After 5 min, the solution of acryloyl chloride (1.7 mL, 0.021 moles) in DCM (15 mL) was added dropwise and stirred for 30 min at 0  $^\circ\text{C}$ . The completion of reaction was checked by TLC using methanol: DCM (5%) as mobile phase. Saturated solution of  $\text{NaHCO}_3$  (20 mL) was added to the reaction mixture and stirred for more 15 min then extracted with DCM (20 mL X 3). The organic layer was washed with  $\text{NaHCO}_3$  (10 mL), dried over  $\text{Na}_2\text{SO}_4$  and evaporated under reduced pressure to get, was purified by prep-HPLC; column: TriArt C18\*250\*20\*mm\*5 $\mu$ m mobile phase: 0.1%  $\text{NH}_3$  in  $\text{H}_2\text{O}$  B: ACN(25:75) to afford 1-(4-acryloyl-

3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (1.2 g). <sup>1</sup>H-NMR (400 MHz) (CDCl<sub>3</sub>): 7.77-7.75 (m, 1H), 7.66-7.62 (m, 1H), 7.53-7.51 (m, 1H), 7.46-7.41 (m, 1H), 7.36-7.32 (m, 1H), 7.28-7.19 (m, 1H), 6.59 (bs, 1H), 6.37 (m, 1H), 5.82 (m, 1H), 4.65-4.54 (m, 1H), 4.32-4.12 (m, 2H), 3.90-3.82 (m, 4H), 3.62-3.52 (m, 2H), 3.45-3.47 (m, 1H), 2.70-2.62 (m, 4H), 2.52-2.42 (m, 5H), 2.34 (s, 3H), 1.87-1.85 (m, 1H), 1.82-1.78 (m, 1H), 1.76-1.72 (m, 6H). MS (m/z): 610.4 (M+1). HPLC purity: 97.16%.

Racemic mixture of **1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile** (1.2 gm) was subjected by chiral separation using CHIRALCEL-ODH (4.6 X 250 mm) 5 µm and mobile phase; acetonitrile (100%): 0.1 % DEA to get and 1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (Isomer 1) (0.51 gm) and 1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (Isomer 2) (0.49 gm )

**Example 24 : 1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (Isomer 1) :** <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): δ 7.78-7.75 (m, 1H), 7.67-7.63 (m, 1H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.52-7.51 (m, 2H), 7.49-7.41 (m, 1H), 7.37-7.33 (m, 1H), 7.29-7.26 (m, 1H), 6.63-6.56 (m, 1H), 6.39 (d, *J* = 16.8 Hz, 1H), 5.83 (d, *J* = 11.2 Hz, 1H), 5.12-5.10 (m, 1H), 4.64-4.56 (m, 1H), 4.38-4.29 (m, 2H), 4.01-3.83 (m, 3H), 3.68-3.59 (m, 2H), 3.41-3.38 (m, 1H), 3.22-3.05 (m, 4H), 2.94-2.84 (m, 1H), 2.75-2.62 (m, 3H), 2.54 (s, 3H), 2.35-2.33 (m, 1H), 2.09-2.02 (m, 1H), 1.88-1.73 (m, 1H). MS (m/z): 610.4 [M+H]<sup>+</sup>. HPLC purity: 97.6%. chiral purity : 99.01%.

**Example 25 : 1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (Isomer 2):** <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): δ 7.78-7.76 (m, 1H), 7.67-7.63

(m, 1H), 7.53 (d,  $J = 7.6$  Hz, 1H), 7.49-7.42 (m, 1H), 7.37-7.33 (m, 1H), 7.29-7.26 (m, 1H), 6.59-6.56 (m, 1H), 6.39 (d,  $J = 16.8$  Hz, 1H), 5.83 (d,  $J = 10.4$  Hz, 1H), 5.12 (bs, 1H), 4.64-4.56 (m, 1H), 4.42-4.29 (m, 2H), 4.01-3.83 (m, 3H), 3.69-3.59 (m, 1H), 3.42-3.38 (m, 1H), 3.23-3.04 (m, 4H), 2.91-2.77 (m, 2H), 2.71-2.67 (m, 1H), 2.55 (s, 3H), 2.40-2.33 (m, 1H), 2.10-2.03 (m, 2H), 2.01-1.73 (m, 5H). MS (m/z): 610.4 [M+H]<sup>+</sup>. HPLC purity: 98.9%, chiral purity : 99.6%

**Example 26: 6-(8-chloronaphthalen-1-yl)-1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.:** To a suspension of 6-(8-chloronaphthalen-1-yl)-1-(3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile hydrochloride (1.8 gm, 0.00324 mol) in ethyl acetate (10.8 mL) at 0 °C was added triethylamine (3.6 mL, 0.02592 mol), 2-fluoroprop-2-enoic acid (0.58 gm, 0.00647 mol) and T3P (6.2 mL, 0.00972 mol, 50 wt. % in ethyl acetate). The mixture was warmed to 15 °C for 30 min and the reaction mixture was diluted with sat aq sodium carbonate (40 mL). The aqueous phase was extracted with ethyl acetate (100 mL X 2) and the combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to provide the crude residue. The residue was purified by prep-HPLC; column: Sunfire C 18 150 × 50 mm × 10 µm, mobile phase: A: water (10 mM NH<sub>4</sub>HCO<sub>3</sub>), B: ACN, B%: 25%–55%, to afford 6-(8-chloronaphthalen-1-yl)-1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.42 gm, 20.64%).

**Example 27: 6-(8-chloronaphthalen-1-yl)-1-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile :** 6-(8-chloronaphthalen-1-yl)-1-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.075 gm, chiral purity: 99%) was isolated by chiral separation using CHIRALCEL-ODH (4.6 X 250 mm) 5 µm and mobile phase; acetonitrile (100%) from the racemic mixture of 6-(8-chloronaphthalen-1-yl)-1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.42 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): δ 7.79-7.76 (m, 1H), 7.67-7.63 (m, 1H), 7.53 (d,  $J = 7.2$  Hz, 1H), 7.49-7.42 (m, 1H), 7.37-7.33 (m, 1H), 7.29-7.26 (m, 1H), 5.48-5.36 (m, 1H), 5.28-

5.23 (m, 1H), 4.64-4.56 (m, 1H), 4.38-4.27 (m, 2H), 4.09-3.81 (m, 3H), 3.67-3.59 (m, 2H), 3.51-3.45 (m, 1H), 3.41-3.36 (m, 1H), 3.29-3.10 (m, 4H), 2.99-2.89 (m, 2H), 2.74-2.70 (m, 2H), 2.53 (s, 3H), 2.36-2.29 (m, 1H), 2.10-1.98 (m, 1H), 1.89-1.61 (m, 3H), 1.29-1.23 (m, 1H). MS (m/z): 628.3 [M+H]<sup>+</sup>. HPLC purity: 97.6%.

**Example 28: 6-(8-chloronaphthalen-1-yl)-1-((R)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile** : 6-(8-chloronaphthalen-1-yl)-1-((R)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.095 gm, chiral purity: 99%) was isolated by chiral separation using CHIRALCEL-ODH (4.6 X 250 mm) 5 µm and mobile phase; acetonitrile (100%) from the racemic mixture of 6-(8-chloronaphthalen-1-yl)-1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile (0.42 gm). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): δ 7.79-7.76 (m, 1H), 7.67-7.63 (m, 1H), 7.53 (d, J = 7.2 Hz, 1H), 7.49-7.42 (m, 1H), 7.37-7.33 (m, 1H), 7.29-7.26 (m, 1H), 5.48-5.36 (m, 1H), 5.28-5.23 (m, 1H), 4.64-4.56 (m, 1H), 4.38-4.27 (m, 2H), 4.09-3.81 (m, 3H), 3.67-3.59 (m, 2H), 3.51-3.45 (m, 1H), 3.41-3.36 (m, 1H), 3.29-3.10 (m, 4H), 2.99-2.89 (m, 2H), 2.74-2.70 (m, 2H), 2.53 (s, 3H), 2.36-2.29 (m, 1H), 2.10-1.98 (m, 1H), 1.89-1.61 (m, 3H), 1.29-1.23 (m, 1H). MS (m/z): 628.3 [M+H]<sup>+</sup>. HPLC purity: 97.6%.

**Example 29: 1-(4-acryloylpiperazin-1-yl)-6-benzyl-3-chloro-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile** : To a solution of intermediate 4 (0.2 g, 0.5 mmol) was dissolved in dry DCM (10 ml), followed by addition of DIPEA (0.3 g, 1.5 mmol) and stirred reaction mixture for 20 min at 0°C. Acryloyl chloride (0.053 g, 0.6 mmol) was added dropwise in the reaction mixture and stirred same temperature for 30 min. The reaction mixture was diluted with DCM and washed with water. The organic layer was dried over sodium sulphate and concentrated under reduced pressure to afford the title solid compound, yield (20 mg). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 7.36-7.29 (m, 5H), 6.60-6.54 (m, 1H), 6.34-6.30 (m, 1H), 5.75-5.73 (m, 1H), 3.80 (s, 4H), 3.68-3.65 (m, 4H), 3.43-3.41 (m, 4H), 2.67-2.59 (m, 4H). MS (m/z): 422.19 [M+H]<sup>+</sup>. HPLC purity : 97.38 %.

**Example 30 : N-(1-(6-benzyl-3-chloro-4-cyano-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperidin-4-yl)acrylamide :** To a solution of intermediate 7 (0.2 g, 52 mmol) was dissolved in dry DCM (10 ml), followed by addition of DIPEA (0.23g, 157 mmol) and stirred reaction mixture for 20 min at 0°C. Acryloyl chloride (0.2 g, 62 mmol) was added dropwise in the reaction mixture and stirred same temperature for 30 min. The reaction mixture was diluted with DCM and washed with water. The organic layer was dried over sodium sulphate and concentrated under reduced pressure to afford the title solid compound, yield (25 mg). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 8.32 (s, 1H), 7.36-7.34 (m, 5H), 6.31-6.27 (m, 1H), 6.09-6.03 (m, 1H), 5.67-5.65 (m, 1H), 5.43-5.41(d, 1H), 4.41-4.08 (m, 1H), 3.80 (s, 2H), 3.75-3.71 (m, 4H), 3.06-3.01 (m, 2H), 2.70-2.62 (m, 4H), 2.08-2.03 (m, 2H), MS (m/z): 402.21 [M+H]<sup>+</sup>. HPLC purity: 97.00 %.

**Example 31 : N-(1-(6-benzyl-4-cyano-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperidin-4-yl)acrylamide :** To a solution of intermediate 6 (0.12 g, 31 mmol) was dissolved in dry DCM (10 ml), followed by addition of DIPEA (0.17 g, 91 mmol) and stirred reaction mixture for 20 min at 0°C. Acryloyl chloride (0.033 g, 35 mmol) was added dropwise in the reaction mixture and stirred same temperature for 30 min. The reaction mixture was diluted with DCM and washed with water. The organic layer was dried over sodium sulphate and concentrated under reduced pressure to afford the title solid compound, yield (25 mg). <sup>1</sup>H-NMR (δ ppm, CDCl<sub>3</sub>, 400 MHz): 7.36-7.27 (m, 5H), 6.30-6.27 (m, 1H), 6.08-6.03 (m, 1H), 5.67-5.65 (m, 1H), 5.43-5.41(d, 1H), 4.14-4.10 (m, 1H), 3.80 (s, 4H), 3.78-3.68 (m, 2H), 3.09-3.04 (m, 2H), 2.64-2.61 (m, 5H), 2.21-2.02 (m, 3H), MS (m/z): 436.12 [M+H]<sup>+</sup>. HPLC purity: 96.25 %.

Other intermediates required to prepare any of the above examples and other illustrated compounds can be synthesized using the general and specific process as described herein above with all possible variation required to synthesize the said intermediates and compounds as envisaged herein.

### **PART C : Biological Activity**

#### **Test 1: In Vitro Cell Proliferation Assay in NCI-H358 and MIAPACA-2 Cell Lines**

Growth inhibition assays is to be carried out using 10% FBS supplemented media. Cells are to be seeded at a desired concentration of 1500-6,000 cells/well in a 96-well plate. Test compounds at a concentration range from 1 to 30 uM will be added after 24 hours. Growth will be assessed using

the CCK-8 kit for measuring reduction at 0 h (prior to the addition of the test compound) and 72 hours after the addition of test compound. Absorbance read on a BIO-RAD iMark Microplate or any equivalent micloplate reader at a wavelength of 450 nm. Data will be analyzed and percent inhibition due to the test compound compared to the control is calculated accordingly.

| Examples                                                                                                                                                          | % Inhibition of Cell Proliferation |     |      |     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-----|------|-----|
|                                                                                                                                                                   | MiaPaca                            |     | H358 |     |
|                                                                                                                                                                   | TC1                                | TC2 | TC1  | TC2 |
| <b>Ex 1</b>                                                                                                                                                       | NT                                 | D   | NT   | NT  |
| <b>Ex 8</b>                                                                                                                                                       | B                                  | D   | NT   | NT  |
| <b>Ex 9</b>                                                                                                                                                       | D                                  | D   | NT   | NT  |
| <b>Ex 10</b>                                                                                                                                                      | D                                  | D   | NT   | NT  |
| <b>Ex 11</b>                                                                                                                                                      | D                                  | D   | NT   | NT  |
| <b>Ex 12</b>                                                                                                                                                      | C                                  | D   | NT   | NT  |
| <b>Ex 13</b>                                                                                                                                                      | D                                  | D   | NT   | NT  |
| <b>Ex 14</b>                                                                                                                                                      | D                                  | D   | NT   | NT  |
| <b>Ex 15</b>                                                                                                                                                      | D                                  | D   | NT   | NT  |
| <b>Ex 17</b>                                                                                                                                                      | D                                  | D   | NT   | NT  |
| <b>Ex 18</b>                                                                                                                                                      | D                                  | D   | NT   | NT  |
| <b>Ex 19</b>                                                                                                                                                      | D                                  | D   | NT   | NT  |
| <b>Ex 20</b>                                                                                                                                                      | C                                  | D   | NT   | NT  |
| <b>Ex 21</b>                                                                                                                                                      | C                                  | C   | NT   | NT  |
| <b>Ex 23</b>                                                                                                                                                      | D                                  | D   | D    | D   |
| <b>Ex 24</b>                                                                                                                                                      | D                                  | D   | D    | D   |
| <b>Ex 25</b>                                                                                                                                                      | D                                  | D   | D    | D   |
| <b>Ex 26</b>                                                                                                                                                      | NT                                 | NT  | B    | D   |
| <b>Ex 27</b>                                                                                                                                                      | NT                                 | NT  | C    | D   |
| <b>Ex 28</b>                                                                                                                                                      | D                                  | D   | C    | D   |
| <b>A= ≤25 % ; B = &gt;25 to ≤ 50 ; C= &gt;50 to ≤ 75 ; D = &gt;75 % to 100 %</b><br><b>TC1: Test Concentartion of 3 uM &amp; TC1: Test Concentartion of 10 uM</b> |                                    |     |      |     |


The present invention has been described above with the aid of functional building blocks illustrating the implementation of specified functions and relationships thereof. The boundaries of these functional building blocks have been arbitrarily defined herein for the convenience of the description. Alternate boundaries can be defined so long as the specified functions and relationships thereof are appropriately performed.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art, readily

modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance

We Claim:

1. A compound of formula **(A)**



**(A)**

or a pharmaceutically acceptable salt, stereoisomer, isotope or prodrug thereof,

wherein

$R^a$  at each occurrence is independently selected from hydrogen, hydroxy, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy,  $-C(=O)OR^b$ ,  $-C(=O)R^b$ ,  $-C(=S)R^b$ ,  $-C(=O)NR^bR^c$ ,  $-C(=O)ONR^bR^c$ ,  $-NR^bR^c$ ,  $-NR^b-OR^c$ ,  $-NR^bC(=O)NR^bR^c$ ,  $-NR^bS(=O)R^c$ ,  $-NR^bS(=O)_2R^c$ ,  $-NR^b-OR^c$ ,  $=N-NR^bR^c$ ,  $-NR^bC(=O)OR^c$ ,  $-NR^bC(=O)R^c$ ,  $-NR^bC(=S)R^c$ ,  $-NR^bC(=S)NR^bR^c$ ,  $-SONR^bR^c$ ,  $-SO_2NR^bR^c$ ,  $-OR^b$ ,  $-OR^bC(=O)NR^bR^c$ ,  $-OR^bC(=O)OR^c$ ,  $-OC(=O)R^b$ ,  $-OC(=O)NR^bR^c$ ,  $-R^bNR^cC(=O)R^b$ ,  $-R^bOR^c$ ,  $-R^bC(=O)OR^c$ ,  $-R^bC(=O)NR^bR^c$ ,  $-R^bC(=O)R^c$ ,  $-R^bOC(=O)R^c$ ,  $-SR^b$ ,  $-SOR^c$ ,  $-SO_2R^b$ ,  $-CR^bR^cC(=O)R^b$  or  $-CR^bR^cC(=S)R^z$  or any two  $R^a$  may be joined to a form a substituted or unsubstituted saturated or unsaturated 3-6 member ring, which may optionally include heteroatoms which may be same or different and are selected from O, NR<sup>a</sup> or S or ; any two  $R^a$  attached to the same carbon atom may be joined to a form a Oxo ( $C=O$ ), Imino ( $=NR^b$ ),  $C=S(O)_p$ , or substituted or unsubstituted saturated or unsaturated 3-6 member ring, which may optionally include heteroatoms which may be same or different and are selected from O, NR<sup>a</sup> or S.

$A_1$  is absent or is independently selected from substituted or unsubstituted  $C_{1-4}$  alkyl, substituted or unsubstituted  $C_{2-4}$  alkenyl, substituted or unsubstituted  $C_{2-4}$  alkynyl, substituted or unsubstituted  $C_{3-10}$  cycloalkyl, substituted or unsubstituted  $C_{3-10}$  heterocycloalkyl,  $-(CR^bR^c)_p$ , O, S,  $-S(=O)_p$ ,  $-C(=O)-$ ,  $-NR^x$ ,  $-CO-NR^x$  and  $-NR^x-CO-$ .

$A_2$  is absent or is independently selected from substituted or unsubstituted  $C_{1-4}$  alkyl, substituted or unsubstituted  $C_{2-4}$  alkenyl, substituted or unsubstituted  $C_{2-4}$  alkynyl, substituted or

unsubstituted C<sub>3-10</sub> cycloalkyl, substituted or unsubstituted C<sub>3-10</sub> heterocycloalkyl, -(CR<sup>b</sup>R<sup>c</sup>)<sub>p</sub>-, O, S, -S(=O)<sub>p</sub>-, -C(=O)-, -NR<sup>x</sup>-, -CO-NR<sup>x</sup>- and -NR<sup>x</sup>-CO-.

Cy<sup>1</sup> is selected from a cyclic group selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl.

Cy<sup>2</sup> is selected from a cyclic group selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl which is optionally substituted by E.

E is a group capable of forming a covalent bond or an “Electrophile” or “electrophilic moiety capable of forming a covalent bond

R at each occurrence is independently selected from CN (Cyano), COOH, CONH<sub>2</sub>, SO<sub>3</sub>H, C(=O)OR<sup>b</sup>, -C(=O)R<sup>b</sup>, -C(=S)R<sup>b</sup>, -C(=O)NR<sup>b</sup>R<sup>c</sup>, -C(=O)ONR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>C(=O)NR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>S(=O)R<sup>c</sup>, -NR<sup>b</sup>S(=O)<sub>2</sub>R<sup>c</sup>, -NR<sup>b</sup>-OR<sup>c</sup>, =N-NR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>C(=O)OR<sup>c</sup>, -NR<sup>b</sup>C(=O)R<sup>c</sup>, -NR<sup>b</sup>C(=S)R<sup>c</sup>, -NR<sup>b</sup>C(=S)NR<sup>b</sup>R<sup>c</sup>, -SONR<sup>b</sup>R<sup>c</sup>, -SO<sub>2</sub>NR<sup>b</sup>R<sup>c</sup>, -OR<sup>b</sup>, -OR<sup>b</sup>C(=O)NR<sup>b</sup>R<sup>c</sup>, -OR<sup>b</sup>C(=O)OR<sup>c</sup>, -OC(=O)R<sup>b</sup>, -OC(=O)NR<sup>b</sup>R<sup>c</sup>, -R<sup>b</sup>NR<sup>c</sup>C(=O)R<sup>b</sup>, -R<sup>b</sup>OR<sup>c</sup>, -R<sup>b</sup>C(=O)OR<sup>c</sup>, -R<sup>b</sup>C(=O)NR<sup>b</sup>R<sup>c</sup>, -R<sup>b</sup>C(=O)R<sup>c</sup>, -R<sup>b</sup>OC(=O)R<sup>c</sup>, -SR<sup>b</sup>, -SOR<sup>c</sup>, -SO<sub>2</sub>R<sup>b</sup>, -CR<sup>b</sup>R<sup>c</sup>C(=O)R<sup>b</sup> or -CR<sup>b</sup>R<sup>c</sup>C(=S)R<sup>z</sup>.


R<sup>1</sup> at each occurrence is independently selected from hydrogen, hydroxy, halogen, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, C(=O)OR<sup>b</sup>, -C(=O)R<sup>b</sup>, -C(=S)R<sup>b</sup>, -C(=O)NR<sup>b</sup>R<sup>c</sup>, -C(=O)ONR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>C(=O)NR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>S(=O)R<sup>c</sup>, -NR<sup>b</sup>S(=O)<sub>2</sub>R<sup>c</sup>, -NR<sup>b</sup>-OR<sup>c</sup>, =N-NR<sup>b</sup>R<sup>c</sup>, -NR<sup>b</sup>C(=O)OR<sup>c</sup>,

-NR<sup>b</sup>C(=O)R<sup>c</sup>, -NR<sup>b</sup>C(=S)R<sup>c</sup>, -NR<sup>b</sup>C(=S)NR<sup>b</sup>R<sup>c</sup>, -SONR<sup>b</sup>R<sup>c</sup>, -SO<sub>2</sub>NR<sup>b</sup>R<sup>c</sup>, -OR<sup>b</sup>, -OR<sup>b</sup>C(=O)NR<sup>b</sup>R<sup>c</sup>, -OR<sup>b</sup>C(=O)OR<sup>c</sup>, -OC(=O)R<sup>b</sup>, -OC(=O)NR<sup>b</sup>R<sup>c</sup>, -R<sup>b</sup>NR<sup>c</sup>C(=O)R<sup>b</sup>, -R<sup>b</sup>OR<sup>c</sup>, -R<sup>b</sup>C(=O)OR<sup>c</sup>, -R<sup>b</sup>C(=O)NR<sup>b</sup>R<sup>c</sup>, -R<sup>b</sup>C(=O)R<sup>c</sup>, -R<sup>b</sup>OC(=O)R<sup>c</sup>, -SR<sup>b</sup>, -SOR<sup>c</sup>, -SO<sub>2</sub>R<sup>b</sup>, -CR<sup>b</sup>R<sup>c</sup>C(=O)R<sup>b</sup> or -CR<sup>b</sup>R<sup>c</sup>C(=S)R<sup>z</sup>.

each occurrence of R<sup>b</sup> and R<sup>c</sup> is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic ring, substituted heterocyclalkyl ring, or substituted or unsubstituted amino, or any two of R<sup>x</sup> and R<sup>y</sup> when bound to a common atom may be joined to form (i) a substituted or unsubstituted saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR<sup>x</sup> or S, or (ii) an oxo (=O), thio(=S) or imino(=NR<sup>x</sup>) group; and

each occurrence of p is independently 0, 1 or 2.

2. A compound of formula




**(A-I)**


wherein all the variables are as defined in claim 1

3. A compound of formula (A) or (A-1) wherein


Cy1 is selected from




Cy2 is selected from



Each of R<sup>a</sup> is Hydrogen




E is selected form





4. A compound of claim 1-3, wherein  $R^a$  is Hydrogen or alkyl
5. A compound of claim 1-4, wherein two  $R^a$  attached to same carbon atom form a  $C=O$  (Oxo) group.
6. A compound of claim 1-6, wherein  $A_1$  is absent or is  $-CR^bR^c-$ ; wherein each of  $R^b$  and  $R^c$  is independently selected from hydrogen, substituted or unsubstituted alkyl.
7. A compound of claim 1-7, wherein  $A_1$  is absent or is  $-CR^bR^c-$ ; where in  $R^b$  is independently methyl or ethyl and  $R^c$  is hydrogen.

- [illegible]





16. A compound of claim 1-15, wherein A<sub>1</sub> is absent or -CH<sub>2</sub> or -(C=O)
17. A compound of claim 1-16, wherein Cy<sup>1</sup> is selected form a cyclic group selected from substituted or unsubstituted heterocyclcyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl.
18. A compound of claim 1-17, wherein Cy<sup>1</sup> is selected form a cyclic group selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
19. A compound of claim 1-18, wherein Cy<sup>1</sup> is selected form






20. A compound of claim 1-19, wherein  $Cy^2$  is selected from cyclic group selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocyclyl and substituted or unsubstituted heterocyclylalkyl.
21. A compound of claim 1-20, wherein  $Cy^2$  is selected from cyclic group selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocyclyl and substituted or unsubstituted heterocyclylalkyl when each group is optionally further substituted with group E.
22. A compound of claim 1-21, wherein R is Cyano (CN).
23. A compound of claim 1-22,  $A_2$  is absent.
24. A compound of claim 1-23, wherein  $Cy^2$  is selected from






substituted with E a group capable of forming a covalent bond.


25. A compound of claim 1-24, wherein E is selected from




26. A compound of claim 1-25, wherein E is selected from



27. A compound of claim 1-26, wherein A<sub>2</sub>-Cy<sup>2</sup>-E is selected from





28. A Compound selected from

1-(4-acryloylpiperazin-1-yl)-3-(1,1-dioxidothiomorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;

1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-morpholino-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;

1-(4-acryloylpiperazin-1-yl)-3-(2-morpholinoethoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;

1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(2-morpholinoethoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;

3-(4-acryloylpiperazin-1-yl)-1-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.;

3-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-1-(2,6-dimethylmorpholino)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;

3-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-1-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.;

(S)-1-(4-acryloylpiperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.;

(S)-1-(4-acryloylpiperazin-1-yl)-6-(3-hydroxynaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;

(S)-1-(4-(2-fluoroacryloyl)piperazin-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-6-(quinazolin-4-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.;

(S)-6-(8-chloronaphthalen-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-1-(4-(vinylsulfonyl)piperazin-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.;

6-(8-chloronaphthalen-1-yl)-1-(4-(2-fluoroacryloyl)-3-methylpiperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.

1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(2,6-dimethylmorpholino)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.

1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.

1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(3-hydroxynaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.

1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-6-(naphthalen-1-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.

(S)-1-(4-acryloylpiperazin-1-yl)-6-(isoquinolin-4-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.

(S)-1-(4-acryloylpiperazin-1-yl)-3-((1-methylpyrrolidin-2-yl)methoxy)-6-(quinolin-8-yl)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:

1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

6-(8-chloronaphthalen-1-yl)-1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.

6-(8-chloronaphthalen-1-yl)-1-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;  
 6-(8-chloronaphthalen-1-yl)-1-((R)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;  
 1-(4-acryloylpiperazin-1-yl)-6-benzyl-3-chloro-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;  
 N-(1-(6-benzyl-3-chloro-4-cyano-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperidin-4-yl)acrylamide; and  
 N-(1-(6-benzyl-4-cyano-5,6,7,8-tetrahydro-2,6-naphthyridin-1-yl)piperidin-4-yl)acrylamide

29. A compound selected from

1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:  
 1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile  
 1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

30. A compound selected form

1-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile:

31. A compound selected form

1-((R)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

32. A compound selected form

1-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-6-(8-chloronaphthalen-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

33. A compound selected from

6-(8-chloronaphthalen-1-yl)-1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.

6-(8-chloronaphthalen-1-yl)-1-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;

6-(8-chloronaphthalen-1-yl)-1-((R)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile

34. A compound selected from

6-(8-chloronaphthalen-1-yl)-1-(3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile.



35. A compound selected from

6-(8-chloronaphthalen-1-yl)-1-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;


36. A compound selected from

6-(8-chloronaphthalen-1-yl)-1-((R)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-3-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydro-2,6-naphthyridine-4-carbonitrile;

37. A compound Selected from




and




or a

pharmaceutically acceptable salts thereof

38. A compound Selected from




39. A compound Selected form




or a pharmaceutically acceptable salt thereof.


40. A compound Selected from





or a pharmaceutically acceptable salt thereof.

41. A Compound selected from













42. A compound selected from




|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |










43. A Pharmaceutical composition comprising a compound of claim 1-42, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
44. A method for treating cancer in a subject in need thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1-42, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of claim 1-42, or a pharmaceutically acceptable salt thereof.
45. A method of treating a KRAS mediated disorder in a subject in need thereof, in particular KRAS G12 C mediated disorder comprising administering to the subject in need thereof a therapeutically effective amount of a compound of claim 1-42, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of claim 1-42, or a pharmaceutically acceptable salt thereof.
46. Use of a compound of claim 1-42, for treating cancer or a RAS-mediated disorder, in particular KRAS G12 C mediated cancer or disorder in a subject.
47. Use of a compound of claim 1-42 for the manufacture of a medicament for treating cancer or a RAS mediated disorder, in particular KRAS G12 C mediated cancer or disorder in a subject.
48. A method of treating a variety of cancers, such as solid cancer and, more specifically, solid cancers with KRASG12 mutation wherein the method comprises of administering to a subject a Compounds of claim 1-42, or the pharmaceutically acceptable salts and/or compositions thereof.

**ABSTRACT**

The present application relates to novel compounds described herein, the method of preparing the same, its pharmaceutical composition and method for use thereof. In particular the application discloses compounds of formula A or their pharmaceutically acceptable salts thereof.

**Formula (A)**

## Electronic Acknowledgement Receipt

|                                             |                               |
|---------------------------------------------|-------------------------------|
| <b>EFS ID:</b>                              | 44967702                      |
| <b>Application Number:</b>                  | 63308727                      |
| <b>International Application Number:</b>    |                               |
| <b>Confirmation Number:</b>                 | 1070                          |
| <b>Title of Invention:</b>                  | NOVEL ANTICANCER THERAPEUTICS |
| <b>First Named Inventor/Applicant Name:</b> | PRASHANT KASHINATH BHAVAR     |
| <b>Customer Number:</b>                     | 159570                        |
| <b>Filer:</b>                               | Parithosh Kumar Tungaturthi   |
| <b>Filer Authorized By:</b>                 |                               |
| <b>Attorney Docket Number:</b>              | VRT-003-USP2                  |
| <b>Receipt Date:</b>                        | 10-FEB-2022                   |
| <b>Filing Date:</b>                         |                               |
| <b>Time Stamp:</b>                          | 15:27:34                      |
| <b>Application Type:</b>                    | Provisional                   |

### Payment information:

|                                          |                  |
|------------------------------------------|------------------|
| Submitted with Payment                   | yes              |
| Payment Type                             | DA               |
| Payment was successfully received in RAM | \$ 150           |
| RAM confirmation Number                  | E202220F27513497 |
| Deposit Account                          |                  |
| Authorized User                          |                  |

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

|                                                                 |                                |                                    |                                          |                  |                  |
|-----------------------------------------------------------------|--------------------------------|------------------------------------|------------------------------------------|------------------|------------------|
|                                                                 |                                |                                    |                                          |                  |                  |
| File Listing:                                                   |                                |                                    |                                          |                  |                  |
| Document Number                                                 | Document Description           | File Name                          | File Size(Bytes)/ Message Digest         | Multi Part /.zip | Pages (if appl.) |
| 1                                                               | Provisional Cover Sheet (SB16) | VRT-003-USP2_CoverSheet_sb0016.pdf | 310347                                   | no               | 3                |
|                                                                 |                                |                                    | 0773cf5ae82c842bd1decd9207657acd566d9c55 |                  |                  |
| Warnings:                                                       |                                |                                    |                                          |                  |                  |
| This is not a USPTO supplied Provisional Cover Sheet SB16 form. |                                |                                    |                                          |                  |                  |
| Information:                                                    |                                |                                    |                                          |                  |                  |
| 2                                                               | Specification                  | VRT-003-USP2_Specification.pdf     | 1006460                                  | no               | 76               |
|                                                                 |                                |                                    | d34f3f05ce4f104636404857f634afd40d4efe53 |                  |                  |
| Warnings:                                                       |                                |                                    |                                          |                  |                  |
| Information:                                                    |                                |                                    |                                          |                  |                  |
| 3                                                               | Claims                         | VRT-003-USP2_Claims.pdf            | 540603                                   | no               | 23               |
|                                                                 |                                |                                    | 54aaa2ca65b7595075248a71689004ef9047d6ce |                  |                  |
| Warnings:                                                       |                                |                                    |                                          |                  |                  |
| Information:                                                    |                                |                                    |                                          |                  |                  |
| 4                                                               | Abstract                       | VRT-003-USP2_Abstract.pdf          | 100504                                   | no               | 1                |
|                                                                 |                                |                                    | 8f9d787ca952afc937301d9e9d17c28da88f1546 |                  |                  |
| Warnings:                                                       |                                |                                    |                                          |                  |                  |
| Information:                                                    |                                |                                    |                                          |                  |                  |
| 5                                                               | Fee Worksheet (SB06)           | fee-info.pdf                       | 37024                                    | no               | 2                |
|                                                                 |                                |                                    | 1c28cd99a08b603448ad651bbb496a94e32461e2 |                  |                  |
| Warnings:                                                       |                                |                                    |                                          |                  |                  |
| Information:                                                    |                                |                                    |                                          |                  |                  |
| Total Files Size (in bytes):                                    |                                |                                    | 1994938                                  |                  |                  |

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**